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ABBREVIATIONS 
Human gene symbols are given in accordance with The Genome Database nomenclature. 
Human genes are written in uppercase italic, while proteins are presented by the same letters 
in plain uppercase.   
 
53BP1  tumor protein p53 binding 
protein, 1 
A   Adenine  
AFP  α-fetoprotein 
AT  Ataxia telangiectasia 
ATM  Ataxia telangiectasia mutated 
gene 
ATR   Ataxia telangiectasia- and rad 3-
related 
ATX  autotaxin 
ARF  ADP-Ribosylation Factor related 
BAI1  brain-specific angiogenesis 
inhibitor 1 
Bax  BCL2-associated X protein 
bp   Base pairs 
BER  Base excision repair gene 
BRCA1  Breast cancer 1 gene  
BRCA2   Breast cancer 2 gene  
C   Cytosine   
CDK1   Cyclin-dependent kinase 1 
CDKN1A  Cyclin-dependent kinase inhibitor 
1A (Alternatively; P21/WAF1) 
cDNA   Complementary deoxyribonucleic 
acid 
CHK1  Checkpoint kinase 1 
CHK2   Checkpoint kinase 2 
C-terminal carboxy terminal 
DNA   Deoxyribonucleic acid 
DNA-PK  DNA dependent protein kinase 
DSB  Double strand break 
DSBR1   Double strand break gene 1 
ERBB2 erythroblastic leukemia viral 
oncogene homolog 2 
FANCD2  Fanconi’s anemia gene, 
complementation group D2 
Fas TNF receptor superfamily, 
member 6 
FRAP  FKBP-rapamycin associated 
protein 
FRDA   Friedreich ataxia gene 
G   Guanine 
GADD45 growth arrest and DNA-damage-
inducible 
GD-AIF  GD-apoptosis inducing factor 
H2AX  H2A histone family, member X 
HR  Homologous recombination 
HRAS  v-Ha-ras Harvey rat sarcoma 
viral oncogene homolog 
kb  kilo base 
Killer/DR5 tumor necrosis factor receptor 
superfamily, member 10b 
KU70  KU70 protein 
Ligase IV  ATP dependent DNA ligase 4    
LOH  loss of heterozygosity 
Maspin  serine (or cysteine) proteinase 
inhibitor, clade B (ovalbumin), 
member 5 
MDC1  mediator of DNA damage 
checkpoint 1 
MDM2  mouse double minute 2 homolog 
isoform 
MMR  Mismatch repair gene 
MRE11   Meiotic recombination 11  
MYC  myelocytomatosis oncogene 
mRNA   Messenger ribonucleic acid   
NBS1   Nijmegen breakage syndrome 
gene 1 
NER  Nucleotide excision repair gene 
NHEJ  Non-homologous end-joining 
Noxa   phorbol-12-myristate-13-acetate-
induced protein 1 
N-terminal amino-terminal 
p14ARF  cyclin-dependent kinase inhibitor 
2A 
p21   see CDKN1A 
P53AIP1 p53-regulated apoptosis-inducing 
protein 1 
PCR polymerase chain reaction 
Perp  PERP, TP53 apoptosis effector 
PI-3K  Phosphatidylinositol-3-OH-kinase 
PIDD leucine-rich repeats and death 
domain containing 
Puma BCL2 binding component 3  
PTT Protein truncation test 
RAD N   Radiation protein number N 
RNA   Ribonucleic acid 
RT-PCR Reverse-transcription polymerase 
chain reaction 
SMC1   Structural maintenance of 
chromosomes gene 1-like 1 
SIR  Standardized incidence ration 
T   Thymine 
TNF  tumor necrosis factor 
TGFBR2 transforming growth factor, beta 
receptor II 
TP53   Tumor protein 53 gene 
TRRAP  transformation/transcription 
domain-associated protein 
TSP1  thrombospondin 1 
WAF1   see CDKN1A 
 
Full and alternative names of genes can be found at the Online 
Mendelian Inheritance in Man web site at John Hopkins 
University 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM
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PREFACE 
 
Sir Francis Crick said: “DNA is, in fact, so precious and so fragile that we now know that the 
cell has evolved a whole variety of repair mechanisms to protect its DNA from assaults by 
radiation, chemicals and other hazards. This is exactly the sort of thing that the process of 
evolution by natural selection would lead us to expect” (1988, What Mad Pursuit. Basic 
Books: New York). As Crick pointed out, damage to DNA sparks a highly regulated and 
strictly controlled process in a normal cell. If some of these processes are interrupted, it may 
result in neoplasm and tumour growth.   
 
The main objective of this work has been to investigate genetic alterations in two genes 
encoding proteins involved in cell cycle control and the DNA damage response machinery.  
The ATMa (Ataxia Telangiectasia Mutated) gene is analyzed for mutations in AT (Ataxia 
Telangiectasia) patients and their relatives to estimate the cancer risk for ATM heterozygous 
individuals. These data are also included in a large Nordic epidemiologic study. The TP53 
gene is analyzed for a polymorphism in patients with colon and breast cancer to assess 
whether this polymorphism is associated with mutated TP53 in the cancers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
a The name of the gene can be confusing. The ATM is mutated in AT patients. However, ATM is the name of the 
functional wild type gene. 
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GENETICS AND CANCER – AN OVERVIEW 
 
Cancer is a genetic disease – a result of complex interactions between genetic and non-genetic 
factors like environmental influence.  This disease group is a consequence of accumulation of 
many different genetic changes, like alterations in genes involved in cell proliferation, 
regulation, and defect DNA repair systems. Predisposed individuals carry genetic alterations, 
including mutations, polymorphic variants and epigenetic changes like methylation. These 
germline alterations can initiate cancer development with high or low penetrance. 
Furthermore, additional somatic genetic changes are required for malignant tumour 
development. 
 
Three groups of genes are associated with cancer development when they are altered: proto-
oncogenes, tumour suppressor genes, and DNA repair genes.  
 
Proto-oncogenes stimulate appropriate cell growth and cell division under normal conditions, 
as required for the continued turnover and replenishment of the skin, gastrointestinal tract and 
blood, for example. Mutations in these proto-oncogenes (also known as oncogenes) act 
dominantly and can lead to a gain in function. Cells with activated oncogenes continue to 
grow (or refuse to die) even in the presence of growth inhibition signals. ERBB2, MYC and 
HRAS are examples of oncogenes associated with breast cancer.  
 
While oncogenes encode proteins that stimulate cell division, the tumour suppressor genes 
encode proteins with restraining effects. The main role of tumour-suppressor genes is to 
depress cell proliferation, by either inhibiting cell growth through the cell cycle or by 
promoting programmed cell death (also known as apoptosis). When several of these growth 
brakes are rendered non-functional through epigenetic and genetic changes and oncogenes are 
activated, the cell becomes malignant. Examples of tumours suppressors are the genes 
encoding the retinoblastoma protein, inactivated in retinoblastomas and TP53, which inhibits 
cyclin-dependent kinases and is inactivated in many different tumours. An epidemiological 
study performed on retinoblastomas in 1971 led to the hypothesis that development of the 
disease required two successive mutations (Knudson, 1971). The hypothesis has been 
generalised (Knudson Jr., 1978) and it is referred to as the “two hit model” for 
tumourigenesis.  
 9
 
Figure 1: Knudson’s two-hit hypothesis leading to inactivation of tumour suppressor genes – 
Blue bars indicate inactivated alleles – they can be germline or somatic; LOH is loss of heterozygosity 
by non-disjunction, mitotic recombination or deletion; green dots indicate gene silencing by promoter 
methylation. Some tumour suppressors genes do not need two hits to infer an increased cancer risk. 
(Balmain et al., 2003)              
 
The first step in the tumour suppressor gene inactivation is a mutation (alternatively loss or 
methylation) of one of the two alleles. This mutation is transmitted in the germ-line patients 
with the familial type of the disease, whereas it occurs somatically in sporadic cases. The 
second mutation or “hit” occurs somatically in both hereditary and sporadic cases. For a 
tumour suppressor gene to loose its inhibitory effect on cell proliferation, both parental gene 
copies have to be inactivated or lost.  
 
Unlike oncogenes and tumour-suppressor genes, repair genes do not control cell birth or death 
directly. They repair various DNA damage and therefore indirectly control the rate of 
mutation in the genome. These genes work to keep genetic alterations to a minimum, and 
when they are inactivated, the probability that cells acquire mutations in oncogenes and 
tumour-suppressor genes is increased, thus increasing the risk for development of benign and 
malignant tumours. Examples are nucleotide-excision repair genes (NER), mismatch-repair 
genes (MMR), and base-excision repair genes (BER) whose inactivation can lead to 
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susceptibility to skin and colon tumours, respectively. (Vogelstein et al., 2000) These genes 
are responsible for repairing subtle mistakes made during normal DNA replication or induced 
by exposure to mutagens. As with tumour suppressors, both alleles of stability genes generally 
must be inactivated for a physiological effect to result (Vogelstein and Kinzler, 2004) 
 
While Knudson’s hypothesis was developed before the era of molecular biology, Evidence 
from the recent molecular era also indicates that cancers can arise from small numbers of 
events that affect common cell birth and death processes. Retinoblastomas are still believed to 
follow the two hit hypothesis. Colon cancer can also arise from few genetic changes as shown 
in figure2. 
 
Figure 2: The development of colorectal cancer – has two distinct phenotypes: MSI and CIN. MSI 
is characterized by defects in the mismatch repair systems, leading to mutation in downstream genes 
such as TGFBR2. CIN is characterized by several chromosome aberrations including deletions of 
chromosome arms 17p and 18q, and mutation in TP53. MSI: microsatellite instability; CIN: 
chromosome instability; MMR: mismatch repair genes (Diep, 2002).  
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Any change in base sequence in DNA is considered a mutation. However, common variants 
(> 1% of the population) are determined polymorphisms. Mutations and polymorphisms may 
be harmful, helpful or neither to the cell(s) that have them. Mutations or polymorphisms that 
occur in a germline cell can be passed on to offspring, whereas changes in a somatic cell to 
the next generation of cells. Mutations and polymorphisms can be located in coding regions of 
DNA (exons) or the non-coding regions (introns - include splice sites). Therefore, alterations 
in DNA sequence can have a variety of consequences for protein expression and function, 
including loss or gain of function.  
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Damage to DNA  
 
Crucial to the maintenance of a cell’s genomic integrity is the cellular response to DNA 
damage. The cell cycle is very accurately controlled in a normal cell to avoid accumulation of 
genetic changes. Ideally, an identical copy of the genome is passed onto the next generation of 
cells. There are two basic responses that can be activated due to DNA damage: DNA repair 
systems and apoptosis. If the amount of damage overwhelms the capacity of the survival 
response machinery, apoptosis is initiated (Figure 3).  
 
 
Figure 3: Cellular response to DNA damage. Different types of DNA damage are handled differently 
according to the type of lesion. It is not completely understood how the cell decides which of the two 
mechanisms to use. (Modified from Shiloh, 2003). 
 
However, if the cell cycle control- and/or the DNA repair-mechanisms fail to respond 
appropriately, the cell may be allowed to pass into mitosis with faulty DNA. This 
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compromises tissue and organ function and can lead to uncontrolled cell division, tumour 
growth, and other degenerative diseases (Abraham, 2003). 
 
 
Damage to DNA by ionizing radiation 
 
 
One of the greatest external threats to genomic integrity and cellular viability is ionizing 
radiation (IR). IR is an important tool in medical diagnostics and treatment. Normal x-rays 
such as mammography or enhanced versions such as computer tomography are diagnostic 
tools based on the use of ionizing radiation. Furthermore, IR is often used in various cancer 
treatments alone or in combination with surgery and chemotherapy. IR includes alpha and 
beta particles, gamma- and x-rays and consists of high-speed electrons that have sufficient 
energy to eject electrons (excitation) from atoms in a cell. Ionization and excitation can lead 
to breakage of chemical bonds, including DNA, and the formation of free radicals (Steel, 
2002). The most severe consequence of IR exposure to the cell is single- and double-strand 
DNA breaks (DSBs). Additionally, the risk of double strand DNA breaks is also elevated by 
other factors like ultra violet (UV) light, chemical mutagens, and reactive oxygen 
intermediates.  
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ATM 
 
Ataxia Telangiectasia  
 
Ataxia Telangectiasia is a rare autosomal recessive disease, caused by mutations in the ATM 
gene. The disease incidence is in the range of 1:40 000 – 1:100 000 live births depending on 
ethnic groups (Swift et al, 1986). In Norway, twenty-one AT cases have been reported (Olsen, 
submitted). In the American population, 1% (2,5 million people) is estimated to be carriers of 
a defect ATM geneb.   
 
Typical clinical symptoms are telangiectasias on the eyes (dilated blood vessels), cerebellar 
degeneration, hence ataxia, extreme IR sensitivity, immune defects, chromosomal complexity, 
and predisposition to various cancers, especially leukaemias (Gatti, 1991). ATM can be 
mutated at several locations within the gene leading to different degrees of the disease, some 
more severe than others. Rare cases of AT patients with milder manifestations of the clinical 
or cellular characteristics of the disease have been reported and have been designated as “AT 
variants”. These cases of AT comprise a heterogeneous group characterized by later onset of 
clinical symptoms, slower progression, extended life span compared to most AT patients, 
decreased levels of chromosomal complexity, and cellular radio-sensitivity (Saviozzi et al., 
2002). In these patients, telangiectasia and/or immunodeficiency may be absent, while the 
neurologic features are present.  
 
AT is often discovered when the patient is between 1 and 3 years of age. The first signs of the 
disease are difficulties with control of body posture and body movement. Telangiectasias 
(tiny, red "spider" veins), which appear in the corners of the eyes or on the surface of the ears 
and cheeks, are characteristic of the disease, but are not always present and generally do not 
appear in the first years of lifec. However, by the age of five, these dilated blood vessels in the 
white of the eye normally occur.  
 
It was early noted that children with ataxia telangiectasia were radiation sensitive when two 
AT children died of acute radiation sickness after receiving conventional doses of 
                                                 
b Ataxia Telangiectasia Society, http://www.atsociety.org.uk, Accessed 15. December 2004.  
c National institute of neurological disorders and stroke http://www.ninds.nih.gov/disorders/a_t/a-t.htm#What_is 
Accessed 5. January 2005 
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radiotherapy for their lymphomas (Cunliffe et al., 1975). More recently, testing of radio-
sensitivity on cells from patients has been proposed as an effective way to diagnose AT early, 
as cells from AT patients are more susceptible for radiation than cells from healthy persons 
(Sun et al., 2002). 
 
Approximately half of the AT patients have immune problems, resulting in repeated colds and 
pneumonias. The immunodeficiency is caused by decreased levels of immunoglobulin A, G 
and E (IgA, IgG, and IgE) (Stray-Pedersen et al., 2000). Levels of serum alpha-fetoprotein 
(AFP) are elevated in 95% of patients, making this an important additional diagnostic method 
for AT patients. Why AFP levels are elevated, remains unclear. It has been proposed that AFP 
has a suppressor effect on the development and function of the immune system.  
 
Other features of the disease may include mild diabetes mellitus, premature greying of the 
hair, difficulty swallowing, and delayed physical, and sexual development (Ristow, 2004; 
McKinnon, 2004). However, children with AT usually have normal or above normal 
intelligence. 
 
There is no curative treatment for AT and, currently, no way to slow the progression of the 
disease. Therefore all treatments are symptomatic and supportive. Physical and occupational 
therapy may help maintain flexibility. Speech therapy may also be needed. Gamma-globulin 
injections may be given to help supplement a weakened immune system. However, only a few 
patients reach the age of 50. The cause of death in AT is often pneumonia or chronic lung 
disease, which might result from immunodeficiency and defects in chewing and swallowing 
owing to progressive neurological impairment (McKinnon, 2004). 
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Figure 4: Various cellular features and phenotypes of AT patientsd  
 
 
AT patients and cancer 
 
AT patients have approximately 100 times higher risk of developing cancers than unaffected 
age matched subjects (Swift et al., 1991). Cancer is a disease that results from alterations in 
the genome, therefore many individuals who suffer from syndromes that are characterized by 
defects in DNA damage responses, are also cancer prone (Hoeijmakers, 2001; van Gent et al, 
2001). About 38% of the young AT individuals develop cancer. However, despite the nervous 
system being markedly affected in AT, the tumour types occurring in this disease are 
primarily lymphoma or leukaemia (Gumy-Pause et al, 2004). Typical cytogenetic changes 
seen in tumours from AT individuals often involve aberrant oncogenic rearrangements at the 
T-cell receptor loci. The occurrence of these tumours underscores the requirement for ATM to 
ensure high-fidelity immunoglobulin-gene recombination after the normal DNA breakage and 
processing that occurs during immune system maturation (Liao & Van Dyke, 1999; Perkins et 
al, 2002). Generally, lymphomas in AT patients tend to be of B-cell origin (B-CLL), whereas 
the leukaemias tend to be of the T-CLL type. Other solid tumours, including 
medulloblastomas and gliomas, occur with increased frequency in AT (Gatti et al., 1991). 
                                                 
d ATM mutation database http://www.vmresearch.org/bri_investigators/atminfo.htm#cycle Accessed 31. 
November 2004 
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The ATM and its gene product 
 
ATM, localised to chromosome band 11q23.1 (Gatti et al., 1981), is 150kb long and consists 
of 66 exons (Uziel et al., 1997; Platzer et al., 1996), resulting in approximately 12 kb of 
mRNA (McKinnon, 2004) encoding a large protein consisting of 3056 amino acids and with 
an estimated molecular mass of 350 kDa (Savitsky et al., 1995a). This protein is a member of 
a large conserved eukaryotic family of protein kinases involved in functions like cell cycle 
control, DNA repair, and recombination (Savitsky et al. 1995b). In mammals this family 
includes DNA-damage response proteins such as ATM, ATR, ATX/SMG-1, DNA-PKcs, 
TRRAP and FRAP. Most of the proteins in this family, including ATM, possess a 
serine/threonine kinase activity (Shiloh, 2003). All proteins in this family contain a domain 
with motifs that are typical for the lipid kinase phosphatidylinositol 3-kinase (PI-3K) 
(Savitsky et al., 1995b). They are therefore named PI3K-like protein kinases. (PIKKs).  
 
 
 
Figure 5: Functional domains in the ATM protein (Modified from Shiloh, 2003) 
 
FAT, PI3K, and FATC are common motifs in the human members of the PIKK family (Fig. 
5). The PI3K domain of the ATM protein harbours the catalytic site of the active kinase.  The 
ATM gene product resides mainly in the nucleus of dividing cells. In undamaged cells the 
protein exists in an inactive form as a dimer. In this state the FAT domain of the other 
monomer blocks the catalytic site (Figure 6). As a consequence of rearrangements in the 
chromatin structure (for example caused by DSBs), the PI3K domain autophosphorylates the 
FAT domain, which in turn releases the two molecules from each other’s grip. This leaves 
two fully activated ATM monomers. 
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Figure 6: ATM activation As a dimer, the FAT domain in one of the monomers blocks the kinase-
containing PI3K domain of the other monomer. As a response to changes in the chromatin structure, 
each ATM molecule phosphorylates the other on a serine residue at position 1981 within the FAT 
domain. This releases the two molecules from each other’s grip and the monomers become highly 
active. ATM becomes active a few minutes after the occurrence of DNA damage (Modified from 
Abraham, 2003).     
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ATM – at the apex of DSB signaling 
 
A large number of responses are initiated by double strand breaks (Figure 7). The ATM 
protein is essential in this response to DNA DSBs. The phenotype caused by loss-of -function 
mutations in ATM indicates that ATM is at the apex in the DSB response cascade (Shiloh, 
2003). 
 
 
Figure 7: ATM-mediated activation of cell-cycle checkpoints in response to DSBs. Arrows 
indicate phosphorylation/stimulation. Arrows with a line through indicates inhibitory phosphorylations. 
T-shaped lines indicate cell cycle arrest. ATM regulates most of these pathways except from the 
CHK1 and the RAD17 pathways, which is regulated by ATR. It is also believed that ATR becomes 
more important at later stages to maintain all of these pathways (Shiloh, 2003). 
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Repair of DNA double strand breaks 
 
ATM becomes highly active only a few minutes after DSBs. In response to a DSB, ATM 
divides into two fractions: one chromatin bound and one free portion that are recruited to the 
DSB site. The free ATM strongly adheres to the DSB site and it is believed that it serves as a 
platform for enzymatic reactions that takes place at those sites (Andegeko et al., 2001). ATM 
phosphorylates numerous substrates, either enhancing or repressing their activities (Figure 7). 
 
Figure 8: ATMs activity at the 
double strand break site. (A) 
Several simultaneous events 
occur to ultimately activate 
ATM signal transduction. ATM 
undergoes auto-
phosphorylation to an active 
monomer (B) A histone variant, 
histone H2AX, present within 
chromatin, becomes 
phosphorylated and serves as 
a tethering platform for repair 
factors. The MRE11–RAD50–
NBS1 complex locates to the 
DNA lesion together with 
BRCA1 (C) Assembly of this 
complex facilitates coordinated 
co-localization of active ATM 
together with other factors 
including MDC1and 53BP1. 
BRCA1, MDC1 and 53BP1 are 
also phosphorylated in an ATM 
dependent manner (D) The 
assembly of this multiprotein complex facilitates the cellular response to a DNA double-stranded break 
(McKinnon, 2004). 
 
When a double strand break occurs, there are two different repair mechanisms that can be 
initiated: non-homologous end-joining (NHEJ) or homologous recombination (HR) (Figure 
9). NHEJ is the most predominant in mammalian cells. This mechanism quickly seals the 
breaks at the cost of creating inaccurately repaired DNA with microdeletions. The HR 
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mechanism is much more accurate than the NHEJ mechanism and leaves a completely and 
accurately repaired DNA. HR is a highly structured process involving several protein 
complexes. HR is sister chromatid dependent, meaning that HR is only possible in the G2 
phase of the cell cycle.  
 
Many proteins and protein complexes are involved in both of the mechanisms.  
In the NHEJ mechanism, the KU70-KU80 heterodimer detects the exposed DNA ends and 
recruits the catalytic subunit of the DNA-dependant protein kinase (DNA-PKcs). The DNA-
PKcs is thought to recruit additional proteins to the DNA break. The Ligase IV-XRCC4 
complex finally seals the gap (Shiloh, 2003). 
 
The MRN complex, consisting of the MRE11, RAD50 and NBS1 units, is thought to be 
responsible for carrying out the initial processing of the DSB ends in the HR pathway (Tauchi 
et al., 2002). MRE11 is a nuclease, Rad 50 is an ATPase and NBS1 is a protein responsible 
for assembling the complex. The MRN complex is also involved in meiotic recombination, 
telomere maintenance and checkpoint signaling (Shiloh, 2003).  The important inter-
relationship between ATM and the MRN complex is underscored by the similarity of two 
other syndromes related to AT that result from hypomorphic mutations in NBS1 and MRE11: 
Nijmegen breakage syndrome and AT-like disorder (McKinnon, 2004) 
 
In the HR mechanism the RAD51-BRCA2 complex is crucial for strand invasion and strand 
displacement. This process allows the use of the undamaged sister chromatid as a template for 
resynthesis of the damaged DNA strands.  
 
Defects in genes coding for any of these proteins may lead to an incomplete DSB response 
and increased risk of genomic instability 
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Figure 9: The two mechanisms for repair of DNA double-strand breaks. (Shiloh, 2003) 
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Activation of ATM will, in a cell with wildtype ATM, lead to cell cycle arrest or apoptosis 
(Figure 3) and therefore prevent erroneous DNA to be passed on to a new generation of cells. 
As well as responding to DSBs caused by environmental stress, ATM is also required for 
processing the physiological DNA strand- breaks that occur during meiosis, immune system 
maturation and for telomere maintenance (McKinnon, 2004). ATM controls processes 
involving large portions of chromosomes, in response to DSBs or in mitotic recombination 
and chromosomal segregation (Vogelstein and Kinzler, 2004) and has been classified as a 
stability gene, or caretaker of the genome. 
 
The simplest interpretation for the role of ATM in preventing AT is that it ensures an 
appropriate response to DNA damage. This aspect of ATM function explains the immune-
system defects that require gene rearrangements for immune maturation, and also the 
development of lymphoma or leukaemia. Radiosensitivity is also clearly linked to a defective 
DNA damage response, and sterility results from defects early in meiosis that involves genetic 
recombination events (Barlow et al, 1997). However, some features, such as ocular 
telangiectasia and insulin resistance, are more difficult to reconcile with a defective DNA 
damage response (McKinnon, 2004). 
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ATM mutations 
 
Numerous different mutations have been identified in AT patients. Mutations are found 
throughout the gene in all 66 exons, with no “hot spots”, and seventy percent of the mutations 
result in a truncated protein (Gatti et al., 2001). Milder versions of AT are caused by 
mutations that result in the production of decreased amounts of functional protein, or normal 
amounts with markedly reduced kinase activity (McKinnon, 2004).  
Figure 10: Mutations in the ATM gene detected in AT patients by exone 
 
Recurrent mutations are reported in Norway, the Netherlands, Costa Rica, the English 
Midlands, Italy, Japan, Poland, and among people of Irish English, Utah Mormon and 
Amish/Mennonite descendance (Laake et al., 1998, Gilad et al., 1996; Ejima and Sasaki, 
1998; Sasaki et al., 1998; Stankovic et al., 1998; Telatar et al., 1998).  Most patients have 
inherited a different mutation from each parent and are namely called compound 
heterozygotes. The distribution of mutations in the Nordic AT patients is shown in figure 11. 
 
 
                                                 
e ATM mutation database, http://www.benaroyaresearch.org/investigators/concannon_patrick/images, Accessed 
15. January 2005 
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Figure 11: Spectrum of mutations in the Nordic AT patients. Each mutation is represented by a 
symbol showings its consequence to the transcripts. Mutations in exonic or flanking intronic 
sequences are located in the nearest exon in the ATM transcript. Mutations found more than once are 
placed on top of each other, whereas the unique mutations are placed beside each other. Note that in 
exon 24 there is a Norwegian founder mutation constituting 17 alleles. (Modified from Shiloh, 2003 
and Laake et al., 2000) 
 
The ATM Mutation Database includes over 300 unique mutations in the ATM gene found in 
AT probandsf. The large size of the ATM gene together with the diversity and broad 
distribution of mutations in AT patients has limited the utility of direct mutation screening as 
a diagnostic tool or as a method of carrier identification, except where founder effect 
mutations are involved (Concannon and Gatti, 1997). 
 
 
                                                 
f ATM mutation database, http://www.benaroyaresearch.org/investigators/concannon_patrick/atm.htm, Accessed 
January 16, 2005 
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ATM heterozygotes and cancer  
 
Epidemiological studies 
 
Since 0.5%-1% of the population are estimated ATM mutation carriers, any increased risk of 
cancer associated with ATM carrier status is of public health relevance. In ATM heterozygotes, 
the relative risk of cancer has been estimated to be 3.8 and 3.5 for men and women, 
respectively (Swift et al., 1991). A summary of some studies on cancer risk among AT 
relatives is given in table 1. 
 
Table 1: Epidemiological studies of cancer risk in ATM heterozygotes 
Population No. of families 
No. of 
relatives 
Cancer incidence 
rate p-value Reference  
US 44 574 3.9a < 0.001 Morrell et al., 1990 
US 161 1599 3.8, menb < 0.05 Swift et al., 1991 
   3.5, womenb < 0.05  
   3.0, men<60c < 0.05  
   2.6, women<60c < 0.05  
Nordic 50 1218 1.19d < 0.05 Olsen et al., 2001 
Boldface numbers are statistically significant   
a Blood relatives compared with spouse controls   
b Heterozygous for ATM mutation    
c Mortality rate for all causes    
d Standardized incidence ratio of cancer   
 
Increased risk of breast cancer is clearly associated with ATM heterozyogosity in females. The 
risk of dying because of breast cancer is significantly higher for mothers of AT probands. 
(Swift et al., 1987; Pippard et al., 1988). Table 2 gives a summary of studies on breast cancer 
and the relative risks (RR) in the most updated reports. 
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Table 2: Epidemiological studies of breast cancer risk in female AT relatives 
Population No. of families 
No. of 
relatives 
No. of breast 
cancer cases 
observed 
Breast 
cancer  
risk 
95 % CI References 
US 99 775 25c 3.8 1.7-8,4 Swift et al. , 1987; Swift et al., 
   21, age <60c 2.9 1.1-7.6 1991; Athma et al., 1996 
   12, age >60c 6.4 1.4-28.8   
UK 95 414 6a 1.7 0.7-4.3 Pippard et al., 1998; Easton, 1994; 
   3a,b 3.4 0.7-9.8 Inskip et al., 1999 
France 34 1423 9c 4.0 1.8-7.5 Geoffroy-Perez et al., 2001 
   5 < 45 yrsc 8.4  2.7-19.8  
   4 > 45 yrsc 2.4  0.6-6.1  
Nordic  66 1448 33 1.7 1.2-2.4 Olsen et al., submitted 
countries   6, age <55b 8.1 3.3-17  
      1, age>55b 3.0 0.0-16   
Boldface numbers are statistically significant    
a Breast cancer deaths     
b Mothers of AT patients     
c Obligate ATM heterozygotes (haplotyped/genotyped)    
 
In a study among blood relatives, women with breast cancer were more likely to have been 
exposed to selected sources of ionizing radiation than controls without cancer, suggesting that 
diagnostic or occupational exposure to ionizing radiation increases the risk of breast cancer in 
women heterozygous for ATM (Swift et al., 1991).  
 
Almost seven percent of all breast cancers in the U.S. may occur in women who are AT 
heterozygotes, which is several times greater than the estimated proportion of carriers of 
BRCA1 mutations in breast cancer cases with onset at any age (Athma et al., 1996). The 
increased risk for breast cancer for AT family members has been most evident among 
younger women, leading to an age-specific relative risk model. This model predicted that 8% 
of breast cancers in women under age 40 arise in ATM carriers, compared with 2% of cases 
between 40 and 59 years (Easton, 1994).  
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Molecular studies 
 
The epidemiological studies on AT families indicate an increased risk of cancer among ATM 
heterozygotes, in particular breast cancer among females. Since the ATM gene was isolated 
(Savitsky et al., 1995a), breast cancer patients and controls have been screened for ATM 
mutations to evaluate the public health implications on the use of different diagnostic tools 
and treatment schemes, such as mammographic screening or radiation therapy. However, 
many of the first case-control studies failed to find significant differences between these two 
groups based on the frequency of ATM mutations (Vorechovsky et al, 1996a, 1996b; 
FitzGerald et al., 1997; Chen et al., 1998) leading to a discrepancy between these studies and 
the epidemiological studies. Retrospectively, however, some later studies show an agreement 
between the previous epidemiological and molecular studies based upon reanalysis of their 
data (Bishop and Hopper, 1997). Table 3 gives a summary of some of the largest studies of 
breast cancers and ATM mutations. 
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Table 3: ATM mutations in breast cancer patients 
Reference Material Method 
Truncating 
mutation(s)/ 
patients screened 
Missense 
substitution(s)/ 
alleles screened 
Vorechovsky et al., 1996a Tumours from unselected BC cases SSCP 0/38 5/76
a 
Vorechovsky et al., 1996b BC cases in multiple cancer families SSCP 3/88 12/176 
Appleby et al., 1997 BC cases with ARRT REF 0/23 11/46c 
Fitzgerald et al., 1997 BC cases < 40 years PTT 2/401 patients 2/202 controls NA 
Chen et al., 1998 BC cases from BC families PTT 1/100 NA 
Larson et al., 1998 Sib pairs with BC REC, FA NA 2/66 sibpairsd 
Shayeghi et al., 1998 BC cases with ARRT  CSGE 1/41             29/82e          
 BC cases without ARRT  0/38 32/78
e  
Bebb et al., 1999 Late-onset sporadic BC cases PTT 0/48 NA 
Izatt et al., 1999 BC cases > 40 years SRA 0/100 36/200f 
Oppitz et al., 1999 BC cases with ARRT SSCP 0/11 1/22 
Broeks et al., 2000 
BC cases < 45 years, 
33 with bilateral 
cancer 
PTT 7/82g NA 
Dork et al., 2002 BC cases SSCP 3/1000 460/1000h 
Thorstenson et al., 2003 HBOC families  DHPLC 10/270h NA 
ARRT= adverse reactions to radiation therapy, BC= breast cancer, HBOC= hereditary breast and ovarian cancer 
families, HD=heteroduplex analysis, FA=fragment analysis, NA=not analysed, PTT=protein truncation test, 
REC=restriction enzyme cutting, REF= restriction fragment polymorphism, DHPLC= denaturing high-pressure 
liquid cromatography, RT=radiation treated, SRA= sequence restriction assay, SSCP=single strand conformation 
polymorphism, yPTT=yeast based PTT. 
a Also seen in the corresponding germline sample (4/4 available cases)  
b The proband had at least one additional case of breast cancer, lymphoma, leukemia or gastric cancer in her family
c One polymorphism in exon 24 of the ATM gene (P1055R) and the presence of a rare HRAS1 allele were 
analysed in 66 sib pairs. Breast cancer was associated with the presence of the two rare alleles with an odds ratio 
of 6.9 (95% CI 1.2-38.3) 
d One commonly detected substitution    
e 27 of 36 alleles carried a commonly detected substitution (D1853N)   
f 2 of the alleles carried a commonly detected substitution (D1853N)   
g The splice mutation, IVS-6 T>G was found in three BC cases and has later been found to be an AT causing 
mutation (Dork et al., 2002) 
h Approximately 1 in 50 german BC cases is a carrier of a disease causing ATM mutation, in addition a large 
variety of distinct ATM mutations and variants were found and some were significantly associated with BC 
h Mutations presumed to be disease causing detected in 10 families, both truncating and missense 
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After many of the early studies failed to find an increased incidence of truncating ATM 
mutations in breast cancer cases and as more sensitive methods for detecting mutations were 
developed, focus shifted from merely identifying truncating mutations to detecting all types of 
mutations in the ATM gene. In the early studies on breast cancer patients it was noted that 
missense mutations were detected more frequently than truncating mutations than would have 
been expected based on the profiles found in AT families. This discrepancy between the 
findings of familial studies and those of case-control studies suggests that the two types of 
ATM heterozygosity (i.e., the presence of truncating or missense mutations) infer different 
cancer risks (McConville et al., 1996, Gatti et al., 1999, Meyn, 1999), with missense 
mutations associated with an increased risk of cancer and truncating mutations predominantly 
leading to an AT phenotype. Therefore, some later studies have focused on specific variants 
in the ATM gene in breast cancer cohorts and others on screening the entire ATM gene for 
variants in breast cancer cohorts. Some of these studies are shown in table 4. 
 
One study (Broeks et al., 2000) on Dutch patients with breast cancer concluded that ATM 
heterozygotes have an approximately 9-fold increased risk of developing a type of breast 
cancer characterized by frequent bilateral occurrence, early age at onset, and long-term 
survival. One splice site mutation, IVS10-6T-G, which leads to AT in the homozygous state, 
is particularly associated with breast cancer both in the general population and in high-risk 
breast cancer families (Broeks et al., 2003). This has also been confirmed in other studies 
(Dork et al., 2002). Haplotype analyses revealed one common ancestor in all Dutch mutation 
carriers, and the mutation is estimated to be at least 2000 years old and widely distributed 
across Europe (Broeks et al., 2003).  
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Table 4: Specific alterations in the ATM gene in patients with breast cancer 
Reference Material Mutation/ polymorphism 
Odds 
ratio 95 % CI 
Stankovic et al., 1998 Two AT-families 7271T→G   12.7 SSa 
Chenevix-Trench et al., 
2002 
One multiple  -   
cancer familyb 
7271T→G   13.7 5.1-36.6 
Bretsky et al., 2003 428 BC cases                
426 controls 
L546Vc 3.35 1.27-8.84d
Bernstein et al., 2003 638 unilateral BCe        
511 bilateral BC 
7271T→G   NEf    
NMD NA 
 638 unilateral BC         
511 bilateral BC 
IVS10–6T→G NEg    
NEh NA 
Angele et al., 2003 254 BC, 70 ARRT IVS22-77 T>C  
  IVS48 + 238 C>G
  G5557A 
1.75i 1.09-2.81 
Thorstenson et al., 2003 270 HBOC L1420F 76j  5–1227 
Szabo et al., 2004 961 BC familiesk 7271T→G   ND NA 
    IVS10–6T→G 1.60 0.48-5.35 
Boldface numbers show a statistically significant increased odds ratio   
BC= breast cancer, HBOC= hereditary breast and ovarian cancer families, SS=statistically significant, 
NE=not elevated, NMD= no mutation detected, NA=not applicable, ARRT= adverse reaction to 
radiotherapy 
a p-value 0.025     
b all of the case patients with breast cancer were carriers of the T7271G mutation, as was one woman 
with gastric cancer  
c only sequence variation overrepresented among all high-stage breast cancer cases out of  20 analyzed 
ATM missense variants 
d After correction for multiple comparisons this variant did not attain statistical significance  
e 1149 women of age <51 not selected on the basis of family history of cancer but part of ongoing study 
of bilateral breast cancer 
fdetected in one out of 638 (0.2%) women with unilateral breast cancer   
g detected in eight out of 638 (1.3%) unilateral breast cancer cases   
hdetected in one out of 511 (0.2%) bilateral breast cancer cases   
I In individuals carrying variants on both ATM alleles     
j Observed in seven families who were carriers of L1420F only, not BRCA1, BRCA2 or other ATM 
mutations; 65 families were carriers of other ATM variants which indicates an association between ATM 
variants and breast cancer 
k Families with non-BRCA1/BRCA2 breast cancer from diverse regions   
 
The 7271T-->G ATM mutation (Stankovic et al., 1998; Chenevix-Trench et al., 2002) has 
been shown to be associated with an increased risk of breast cancer in both homozygotes and 
heterozygotes. There is a less severe AT phenotype in terms of the degree of cerebellar 
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degeneration. This mutation (7271T-->G) allows expression of full-length ATM protein at a 
level comparable with that in unaffected individuals. As table 4 shows, these findings have so 
far not been confirmed by later studies.  
 
Preliminary data on breast cancer patients participating in an ongoing study on bilateral 
occurrence of breast cancer, stratified with radiation received for a 1st breast cancer show a 
significantly increased risk of a 2nd cancer (> 4x elevated) in patients with ATM mutations 
leading to conservative amino acid changes (Børressen-Dale, 2005).  
 
So far, the studies on ATM mutations in breast cancer patients conclude that a large variety of 
distinct ATM mutations and variants exist among breast cancer cases and there is a growing 
body of evidence that ATM mutations infer increased susceptibility to breast cancer. Some 
variants are shown to particularly contribute to the etiology and progression of malignancy 
(Thorstenson et al., 2003; Dork et al., 2002; Angele  et al., 2003; Børresen-Dale, 2005). 
 
In humans, different mutation types are proposed to give different cancer risks. Missense 
mutations are proposed to have the most elevated risk. However, to separate missense 
mutations that are “pathogenic” and “non-pathogenic”, cDNA containing these mutations 
have to be inserted into an AT cell line and subsequently radiated. They can be distinguished 
by their capacity to correct the radiosensitive phenotype in AT cells. Pathogenic missense 
mutations abolish the radiation induced kinase activity of ATM in normal control cells, cause 
chromosomal instability and reduced viability in irradiated control cells, whereas the less 
aggressive mutations do not (Scott et al., 2002). The mutant ATM is expressed at the same 
level as endogenous protein, and interference with normal ATM function seems to be by 
multimerization. While truncating mutations usually lead to synthesis of nonfunction protein, 
missense mutations lead to synthesis of a normal level of abnormally functioning ATM 
protein (McConville et al., 1996; Gatti et al., 1999; Meyn, 1999). Since the ATM protein is 
held inactive in dimer or multimer forms (Bakkenist and Kastan, 2003), the presence of a 
defective ATM protein may inhibit activation of the normal protein. A truncated protein has 
little or none effect on the activity of the ATM protein produced by the normal allele in ATM 
heterozygotes and therefore would have little or no effect on the overall function of the 
wildtype ATM. In contrast, the protein encoded by a missense-mutated allele could act as a 
dominant-negative inhibitor of the ATM protein produced by the normal allele. This would 
result in an alteration in the activity of the DNA damage detection and repair system, in which 
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ATM is involved, and therefore in an increase in cancer risk (Chenevix-Trench et al., 2002; 
Scott et al., 2002). An ATM 7636del9 mutant protein of a heterozygous knock-in mice 
displayed dominant-negative activity in cellular assays (Spring et al., 2002) and the mice 
developed an abnormally high number of spontaneous tumours, including a substantial 
number of mammary tumours (Spring et al., 2002). Other results of in vitro studies using cells 
heterozygous for ATM mutations also support the idea that a dominant-negative interaction 
occurs between the normal and mutated forms of the ATM protein.  
 
Cell lines carrying missense mutations are on average more radiosensitive than those carrying 
truncating mutations (Fernet et al., 2004). This is in agreement with the dominant-negative 
interactions involving missense mutations and influencing cells heterozygous for ATM 
mutation’s survival. Studies on extended AT families have failed to detect a significant 
difference in the relative risk of breast cancer or any other type of cancer based on different 
types of ATM mutations (Cavaciuti et al., 2005). However, the occurrence of breast cancer 
may be associated with truncating mutations in regions encoding certain binding domains of 
the ATM protein (e.g., TP53/BRCA1, -adaptin, and FAT domains). Therefore, the risk of BC 
may be associated with the alteration of binding domains rather than with the length of the 
predicted ATM protein.  
 
Detecting mutations in the ATM gene has been one of the greatest challenges in estimating 
cancer risk in ATM heterozygous. With more sensitive techniques available such as DHPLC, 
the association between different ATM gene variants and breast cancer will become clearer in 
the years to come. Expression profiling by microarray techniques may also prove useful in 
detecting ATM heterozygous (Watts et al., 2002). Although the defining characteristic of 
recessive diseases is the absence of a phenotype in heterozygous carriers, the phenotype is 
detectable, in lymphoblastoid cells from AT carriers, as changes in expression level of many 
genes. Carriers of the recessive disease may have an “expression phenotype”, and this might 
prove a new approach to the identification of carriers and enhanced understanding of their 
increased cancer risk. A summary of present knowledge on types of ATM mutations and their 
phenotypes is given in table 5. 
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                                       Table 5: ATM mutations and phenotype 
ATM mutation category Phenotype 
truncating/truncating classical AT 
truncating/missense classical AT 
missense/missensea mild/variant AT 
wt/truncating increased risk of bcb
wt/missensec increased risk of bc
wt/wt wildtype 
a Some variants have an effect on splicing or 
stereofolding of protein in critical domains and give a 
classical AT phenotype in the homozygous state. 
b depending on where the truncating mutation is 
located 
c Some variants are associated with increased risk of 
bc, and radiation sensitivity  
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TP53 
 
Background 
 
The TP53 is probably the most extensively studied molecule in the cancer field (Bos et al., 
2004). The realization that TP53 is a common denominator in human cancer has started an 
avalanche of publications on that field since 1989. Since then there have been over 17,000 
publications on TP53 and over 19,800 tumour-associated mutations in TP53 have been 
discovered (Olivier et al., 2004), ranging from humans to clams (Vogelstein et al., 2000).  
TP53 mutations are common in human cancers, about half of the analysed human tumours. 
Persons that inherit TP53 mutations, develop cancers (especially breast, sarcoma, adrenal, and 
brain) with almost 100% penetrance (Vogelstein et al., 2004). TP53, identified in 1979, was 
originally thought to be a tumour antigen (Lane and Crawford, 1979). Mutant TP53 was 
shown to co-operate with KRAS2, an oncogene, to transform normal cells into neoplastic 
cells, and was therefore for several years believed to be an oncogene. However, its ability to 
abolish the tumourigenic phenotype when transfected into tumour cell lines as well as its 
association with hereditary cancers led to reclassification from oncogene to tumour suppressor 
gene. TP53 is now considered to be the guardian of genome (Lane, 1992; Gottlieb and Oren, 
1996; Ko and Prives, 1996; Levine, 1997; Prives and Hall, 1999; Tlsty, 2002), which 
maintains genomic stability. 
 
 
The TP53 and transcripts 
 
The TP53, located at chromosome band 17p13.1, consists of 11 exons within approximately 
20 kb of genomic DNA (McBride et al., 1986). Exon 1, located 8-10 kb 5’ from exon 2, is 
non-coding. Two promoters have been demonstrated at the 5’-end of the TP53 gene; the first 
is located upstream of exon 1, whereas the second, a stronger promoter, is located within the 
first intron (Reisman et al., 1988). 
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The TP53 protein 
 
The TP53 encodes a 53 kD (hence the name, tumour protein 53) cell cycle regulatory nuclear 
phosphoprotein, which consists of 393 amino acids. TP53s pivotal roles in checkpoint control 
result from its unique biochemical features. It contains at least three domains: (i) The DNA-
binding domain consisting of amino acids from about 100 to 300; this proteolysis-resistant 
core is flanked by (ii) an N-terminal containing a strong transcription activation signal 
(Vogelstein and Kinzler, 1994) and (iii) a complex C-terminal that houses nuclear localisation 
sequences, a homotetramerization domain and a putative DNA damage recognition domain 
(Fei et al., 2003)   
 
 
 
Figure 12: Structural organization of TP53 (Modified from Fei et al., 2003) 
 
 
 
Figure 13: The structure of the core domain of the TP53 
bound to DNA (Cho, et al., 1994) 
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Cellular location and stability 
 
The TP53 is primarily located in the nucleus, but it can be detected in the cytoplasm in G1 
and following DNA synthesis. Under unstressed circumstances, TP53 is present in a latent 
state and is maintained at low levels through targeted degradation. Therefore, the protein is 
undetectable or present at low levels in resting cells, with a half-life of around 20 minutes, 
being rapidly degraded by the cells proteolytic enzymes. A variety of cellular stresses, such as 
insults to the cell causing DNA damage, transiently stabilise the TP53, cause it to accumulate 
in the nucleus, and subsequently activate it as a transcription factor. (Appella and Anderson, 
2000). Stressed and damaged cells are more likely than undamaged cells to contain mutations 
and exhibit abnormal cell cycle control, and therefore present a greater risk of becoming 
cancerous (Vogelstein and Kinzler, 2004).  
 
 
Activation - upstream of TP53 
 
The amount and therefore the activity of TP53 is regulated by many different post-
translational modifications, including phosphorylation, acetylation, ribosylation, O-
glycosylation, ubiquitination and SUMOylation (Fei and El-Deiry, 2003). For example, upon 
DNA damage, TP53 is phosphorylated at ser15, which induces a conformational change that 
makes MDM2 unable to bind TP53 and results in the relief of the inhibitory effect of MDM2 
on TP53. (Shieh et al.,1997). Several important TP53 regulators have emerged, including 
MDM2, a ring-finger ubiquitin ligase that is both a TP53 target gene and a determinant of 
TP53 stability; ARF, an inhibitor of MDM2, which increases the stability of TP53; ATM, 
ATR and CHK1/ CHK2, which can promote TP53 stability by phosphorylating the sites on 
the TP53 protein that interfere with the binding to MDM2; and several coactivators recruited 
by TP53 to promote transcriptional activity (Gu et al., 1997; Espinosa and Emerson, 2001)  
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Function – an overview  
 
The TP53 is one of the key proteins in checkpoint pathways, which coordinates DNA repair 
with cell cycle progression and apoptosis (Fei and El-Deiry, 2003). The TP53 is both a 
caretaker (by inducing DNA repair) and a gatekeeper (by inducing apoptosis in the case of 
irreparable damage). When DNA is damaged, TP53 is activated and the necessary responses 
are induced (Bos et al., 2004). The roles of TP53 as a tumour suppressor are predominantly, if 
not exclusively, mediated through its targets (Fei and El-Deiry, 2003). The TP53 has been 
shown to be a transcription factor regulating genes that can mediate cell cycle arrest and 
apoptosis, facilitate DNA repair, or alter other cellular processes (Levine et al., 2004). The 
biochemical function of TP53 that best explains its effects is its sequence specific 
transcriptional activity, which transactivates target genes through binding a consensus motif 
in their genomic DNA sequences (Bourdon et al., 1997; El-Deiry, 1998; El-Deiry et al., 1992; 
Funk et al., 1992). Wildtype TP53 protein has the capacity to both activate and repress gene 
transcription in order to exert its function in response to genotoxic stress. The function of 
TP53 is to act as a checkpoint responding to a wide variety of stress signals that can originate 
from external or internal events (Levine et al., 2004). DNA damage, hypoxia, heat shock 
(denatured proteins), mitotic spindle damage, nucleoside triphossignificance phate pool sizes, 
nitric oxide signaling, and activation of proto-oncogenes, will all signal to TP53 and elicit a 
specific response by the cell (Vogelstein et al., 2000). TP53 functions as an integrator of the 
upstream signals and then acts as a central node in a signal transduction network that responds 
to minimize mutations and other errors that can lead to cancers or other pathologies 
(Vogelstein et al., 2000).  
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Figure 14: The role of TP53 simplified. A number of cellular stresses, including DNA damage, 
hypoxia and hyperproliferative signals, activate TP53 to stimulate target gene expression. TP53 
induces genes encoding p21 and some other proteins to implement a G1 arrest response and genes 
encoding Bax, Puma, Noxa and Perp to activate the apoptotic pathway. The particular downstream 
pathway activated by TP53 is influenced by cellular context, and both pathways contribute to tumour 
suppression. (Attardi and DePinho, 2004) 
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Response to the activation of TP53 
 
Several dozen genes that are controlled directly by TP53 have been identified (El-Deiry, 
1998), and they fall broadly into four categories based on their effects: cell-cycle inhibition, 
apoptosis, genetic stability, and prevention of blood vessel formation.  
 
One of the results from TP53 expression is a block in the cell cycle. The TP53 protein induces 
the expression of p21WAF1/CIP1, an inhibitor of cyclin-dependent kinases (CDKs). CDKs 
are key regulators of the cell cycle, working together with cyclin proteins to ensure that the 
genome in the daughter cells are identical to the mother cell. Through its negative effects on 
various CDKs, p21WAF1/CIP1 inhibits both the G1-to-S and the G2-to-mitosis transitions. 
(Vogelstein et al., 2000) 
 
Another function of TP53 is activation of the apoptotic pathway. There are several potential 
mediators of TP53-induced apoptosis. The Bax protein is an apoptosis-inducing member of 
the Bcl-2 protein family. Transcription of the Bax gene in some human cells is directly 
activated by TP53-binding sites in the regulatory region of the gene. The NOXA and 
P53AIP1 genes have been shown to be directly activated by TP53 (Oda E et al., 2000; Oda K, 
et al., 2000). Like Bax, NOXA and P53AIP1 proteins are located in mitochondria, and when 
overexpressed, these proteins induce apoptosis. There are other potential mediators of TP53- 
induced apoptosis such as proteins, which belong to the same family as the TNF (tumour 
necrosis factor) receptor and Fas. Additionally, TP53 may cause death by directly stimulating 
mitochondria to produce an excess of highly toxic reactive oxygen species. (Vogelstein et al., 
2000) 
 
Not all cancer genes are involved in the regulation of the cell cycle, like repair genes, which 
are involved in repairing DNA damage. Inactivation of such systems may increase the risk of 
development of cancer. This is because inactivation of these genes leads to an increased risk 
of mutation in tumour suppressor genes or oncogenes (Vogelstein et al., 2000). The TP53 is 
suggested to be important in maintaining genetic stability, but however, the mechanisms are 
not clear. 
 
To grow above a certain size, tumours must establish new blood vessels, also called 
angiogenesis, for transporting nutrients and waste to and from the tumour cells. The wildtype  
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TP53 stimulates the expression of genes that prevent this process. Cells with inactivated TP53 
would therefore be more likely to promote angiogenesis, and therefore provide a critical 
growth advantage at a late point in tumour development. Different studies confirm that 
preventing the formation of new blood vessels can be an important component of the activity 
of a tumour suppressor. The TP53 network is summarized in figure 15. 
 
 
Figure 15: Summary of the TP53 network. TP53 is a highly connected  “node” in this network. It is 
therefore unsurprising that the loss of TP53 function is so damaging, and that such loss occurs in 
nearly all of human cancers. Many other components of this network, not shown here, have also been 
identified (Vogelstein et al., 2000). 
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TP53 mutations and cancers 
 
TP53 germline mutation carriers are considered predisposed to cancer since one TP53 allele is 
mutated in all cells and only one remaining allele needs to be altered by somatic mutation to 
be inactivated according to Knudson’s two hit hypothesis (Donehower, 1996). In fact, 
inherited TP53 mutations are associated with a rare autosomal dominant disorder identified by 
Li and Fraumeni (1969), called the Li-Fraumeni syndrome (LFS). LFS is characterized by 
multiple primary neoplasms in children and young adults, with a predominance of soft-tissue 
sarcomas, osteosarcomas, breast cancer, brain tumors, adrenocortical carcinoma, and 
leukemia. Up to date, there are 264 described germline mutations in 261 families or 
individuals (Olivier et al., 2004).  
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Figure 16: Tumours associated with TP53 germline mutations (Olivier et al., 2004) 
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As previously mentioned, somatic TP53 mutations are found in many tumours. A selection is 
shown in figure 17. 
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Figure 17: Percentage of TP53 mutations in different tumour types (Olivier et al, 2004) 
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Almost all of the different mutant TP53s have a longer half-life than the wildtype, which 
results in an accumulation the protein in the cell. However, the altered protein may 
functionally differ from the wildtype protein. The majority of mutations found in human 
tumours are missense mutations, and these mutations are clustered into region encoding the 
central DNA binding domain (Greenblatt et al., 1994) (Figure 18). 
 
 
Figure 18: Somatic mutations in TP53 – distribution of single base substitutions (Olivier et al., 
2004) 
 
Furthermore, the majority of TP53 missense mutations, accumulate in cancer and are often 
retained in distant metastasis. This suggests that a mutation results in more than a loss of 
function. As previously described for mutated ATM, other properties have also been ascribed 
to mutant TP53 in addition to a loss of function. These include dominant-negative effects over 
wild-type TP53 and/or acquisition of new properties (gain-of-function). However, these 
properties differ from one TP53 mutant protein to anotherg.  
 
 
                                                 
g TP53 mutation database http://www-p53.iarc.fr/p53MUTfunction.html Accessed 20. January 2005 
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Figure 19: Functional properties of TP53 mutants Functional activities or properties of mutant 
proteins have been grouped into five categories: (1) retained wild-type activity, (2) loss of function, (3) 
gain of function, (4) dominant-negative effect, and (5) temperature sensitivity.  
 
 
While the TP53 is mutated in approximately 50-55% of cancers, change in TP53 function 
occurs in an even higher percentage of cancers. In addition to inactivating mutations, TP53 
can be inactivated indirectly through binding to viral proteins, or as a result of alterations in 
genes whose products interact with TP53 or transmit information to or from TP53.  Some 
mechanisms that inactivate TP53 are listed in Table 6. 
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Table 6: The many ways in which TP53 may malfunction in human cancers.  
Mechanisms of inactivating TP53 Typical tumours Effect of inactivation 
Amino-acid changing              
mutation in the DNA-binding 
domain 
Colon, breast, lung, 
bladder, brain, pancreas, 
stomach, oesophagus and 
others 
Prevents TP53 from binding 
to specific DNA sequences 
and activating the adjacent 
genes 
Deletion of the carboxy-terminal 
domain 
Occasional tumours at 
many different sites 
Prevents the formation of 
tetramers of TP53 
Multiplication of the MDM2 gene 
in the genome Sarcomas, brain 
Extra MDM2 stimulates the 
degradation of TP53 
Viral infection Cervix, liver, lymphomas 
Products of viral oncogenes, 
bind to and inactivate TP53 
in the cell, in some cases 
stimulating TP53 degradation
Deletion of the p14ARF gene 
Breast, brain, lung and 
others, especially when 
TP53 itself is not mutated 
Failure to inhibit MDM2 and 
keep TP53 degradation under 
control 
Mislocalisation of TP53 to the 
cytoplasm, outside the nucleus Breast, neuroblastomas 
Lack of TP53 function (TP53 
functions only in the nucleus)
(Modified from Vogelstein et al., 2000) 
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TP53 polymorphisms and cancer 
 
Several DNA polymorphisms in the TP53 have been identified in human populationsh. Most 
reported polymorphisms are localised in introns, outside consensus splicing sites. While these 
sequence variants theoretically could affect TP53 protein function, the consequences of 
intronic variations are unclear. An overview of reported polymorphisms is given in table 7. 
 
Table 7: Polymorphisms in TP53 (Oliver et al.,2004) 
Exon/  
intron Codon 
Nucleotide 
positiona Type
b Base sequence in codon 
Mutated base 
sequence 
Con- 
sequence Prevalence Reference
c 
Polymorphisms that do not alter the amino acid sequence of p53     
Exon 2 21 11779 Point GAC GAT Silent unknown Ahuja et al. (1990) 
Exon 4 34 12026 Point CCC CCA Silent 20 % Vos et al. (2003) 
Exon 4  36 12032 Point CCG CCA Silent  4 % Felix et al. (1994) 
Exon 6  213 13399 Point CGA CGG Silent To 11% Carbone et al. (1991) 
Polymorphisms that do alter the amino acid sequence of p53     
Exon 4  47 12063 Point CCG TCG Pro>Ser  To 1.5 % Felley-Bosco et al. (1993)
Exon 4  72 12139 Point CGC CCC Arg>Pro 
Wide range     
Beckman      
et al. (1994) 
Harris et al. 
(1986) 
Thomas et al. 
(1999) 
Polymorphisms in non-coding regions of the TP53 gened     
Intron 3 - 11951 ins - - 16bp+ Sjalander et al.  (1996) 
 Lazar et al. 
(1993)  
Intron 6 - 13494 Point - - G>A unknown 
Chumakov 
and Jenkins 
(1991) 
aNucleotide position at which the polymorphism is located, based on the GenBank entry X54156.  
b Mutation-type: point=single base substitution, Ins=insertion.    
c Reference where the polymorphism has been described for the first time    
d A total of 15 intronic polymorphisms have been reported to the TP53 mutation database - listed are the most extensively 
studied 
 
                                                 
h TP53 mutation database: http://www-p53.iarc.fr/Polymorphism.html Accessed 24. January 2005 
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Only two polymorphisms, proline to serine at residue 47 and arginine to proline at residue 72, 
alter the amino acid sequence of TP53. The Ser47 variant is a rare polymorphism affecting a 
codon conserved in evolution. Residue 72, although not conserved, is located within the 
proline-rich region and may affect the structure of the putative SH3-binding domain. Ethnic 
differences in codon 72 allele frequencies have been observed. In Western Europe (France, 
Sweden, and Norway), North America (USA), Central and South America (Mexico, Costa-
Rica, Peru) and Japan, the most common allele is Arg72, with frequencies ranging from 0.60 
to 0.83.  
 
TP53 protein with Arginine at position 72 is more efficiently targeted for degradation by the 
E6 protein of HPV16, suggesting that individuals homozygous for Arg72 may be at a higher 
risk of HPV-related cervical cancers (Storey  et al., 1998). However, this hypothesis has not 
been confirmed in human populations (Klug 2001, Koushik 2004).  The codon 72 Pro/Pro 
genotype is associated with an elevated risk of lung cancer (Kawajiri 1993, Wu 2002), 
however others could not confirm this association (Matakidou 2003). Haplotypes with codon 
72 Arg/Pro, intron 6 G>A and intron 3 duplication are associated with increased lung cancer 
risk and correlated with higher apoptotic indices and DNA repair capacity in lymphoblastoid 
cell-lines (Wu 2002). The intron 3 duplication gives an increased risk of colorectal cancer and 
correlates with a reduced level of TP53 mRNA in lymphoblastoid cell-lines (Gemignani 
2004). While further studies on these polymorphisms are needed to enlighten their influence 
on cancer risk, these findings strongly suggest that these polymorphisms may affect TP53 
function. 
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ATM AND TP53 INTERACTION 
 
Both TP53 and ATM have important roles in controlling the integrity of the genome. They 
function in the same DNA damage response pathway, with ATM as an upstream regulator of 
TP53 activity. ATM dependent events leading to TP53 stabilisation represent the initial major 
mechanism by which cells utilize the TP53 pathway for the cellular stress response, leading to 
cellular growth inhibition and tumor suppression (Bakkenist and Kastan, 2003). However, the 
presence of multiple positive regulators of TP53 and numerous downstream targets indicates a 
redundancy that ensures activation of the TP53 pathway (Lozano and Zambretti, 2005). Their 
common role in inhibiting tumourigenesis is confirmed by the phenotypes of the cells and 
individuals, homozygous and heterozygote for mutations in ATM and TP53 (Table 8). 
 
 
Table 8: Comparison of the ATM and TP53 mutated phenotypes (Børresen, 1988) 
Phenotype ATM  TP53 
Cells No G1/S and G2/M arrest after irradiation
No G1/S arrest 
after irradiation 
Predominant cancer in 
homozygous 
Leukaemia and 
lymphoma 
Leukemia and 
lymphoma (mice) 
Most frequent cancer 
in heterozygous Breast  Breast 
 
ATM-deficient cells, have a severe disruption of the G1 checkpoint because the TP53-
dependent response to DNA damage is suppressed (Delia et al., 2003). While ATM 
heterozygous deficient mice, carrying a knock out null allele, have no increased risk of breast 
cancer, doubly heterozygous ATM and TP53 deficient mice have a strong enhancement in 
mammary carcinogenesis following X-ray irradiation (Umesako et al., 2005). Thus, when one 
allele is inactivated in both ATM and in TP53, the cell is unable to respond properly to 
radiation and therefore the risk of cancer development increases. These findings indicate that 
while two “hits” are required for tumourigenesis, these two hits do not have to be in the same 
gene. This hypothesis is illustrated in figure 20.  
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Figure 20: Hypothesis of effects of ATM and TP53 inactivation on cells (Børresen, 1988) 
 
Both mutant ATM and mutant TP53 have demonstrated dominant negative effects over the 
respective wildtype protein, suppressing the tumour suppressor and caretaker function of the 
wildtype protein. The inactivation of one allele of both ATM and TP53 is associated with 
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breast cancer but further studies are needed to enlighten whether specific mutations in ATM 
and TP53, separately and in combination infer an even higher cancer risk in humans.    
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MATERIALS 
 
 
The Nordic and Norwegian AT study 
 
As a part of the Nordic AT study, pediatric neurologists, pediatric immunologists, medical 
geneticists, and the medical staff of cytogenetic laboratories and institutions for disabled 
children were requested to report cases of verified or suspected AT (from 1950 through 1995) 
to the country's study coordinator. Blood samples, lymphoblastoid cell lines or fibroblasts 
were available for most families (58 families), either from the proband (or affected siblings) 
when alive or from the parents. When we were unable to conduct clinical and biochemical 
examinations to verify the AT cases, the relevant information from the medical records was 
obtained and reviewed. No case of AT was identified in Iceland (population, 260 000).  
 
For inclusion in the Nordic study the absolute criterion was progressive cerebellar ataxia. 
Supporting criteria were AT, ocular apraxia, dysarthria, history of infections, elevated 
alphafetoprotein, chromosome rearrangement involving chromosomes 7 and 14 or increased 
chromosomal breakage and decreased IgA or IgG2.  
 
A total of 75 patients within 66 families were included, each of whom was characterized by 
name, sex, and a personal identification number (PIN). The PIN, which incorporates the date 
of birth, is unique to every Nordic citizen and permits accurate linkage of information among 
population and health registers. 1445 relatives were identified and relevant cancer diagnoses 
were obtained from the four countries’ cancer registries. 
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In the Norwegian molecular analysis study, 18 families with a total of 20 probands were 
included, after informed consents were collected and mutation analysis performed. One 
family was excluded of own choice and one family was excluded because no AT mutations 
were found, and the AT diagnosis was not clinically verified. Biological material from 
probands or their parents was used to identify the disease causing mutation as in the Nordic 
study. DNA for mutation analysis was extracted from leukocytes in blood, fibroblasts or 
lymphoblastoid cell lines, using chloroform/phenol extraction followed by ethanol 
precipitation (Nucleic Acid Extractor 340A; Applied Biosystems) according to standard 
procedure (Børresen-Dale et al., 1998b). 
 
350 relatives of the 18 families were identified, and biological material, blood samples or 
paraffin embedded tumour tissue was available from 168 blood relatives in the Norwegian AT 
families. The Norwegian Cancer Registry receives reports of all cancer cases in Norway and 
paraffin embedded tumour tissue was collected from individuals with a cancer diagnosis. 140 
mutation analyses were done on the basis of a blood sample from a live relative and 28 solely 
on the basis of tissue from an archival tumour block, 13 samples were analysed in both. A 
description of the paraffin extraction protocol used is found in the appendix.  
Tracing of relatives for construction of pedigrees was based on data from the computerized 
national civil registration systems of Norway, and information on more distant ancestors was 
derived from manual local population and church registers. 
 
 
The study on the Pro/Arg polymorphism in mutated TP53  
 
The study included 390 Norwegian breast cancer cases. These were from two different 
consecutive series (129 and 130 samples, respectively) previously described for TP53 
mutation status (Andersen et al., 1993; Bukholm et al., 1997) and from two series of 
advanced breast cancer cases (84 and 47, respectively), of which, one had been described 
previously (Geisler et al., 2001). One hundred sixty-two Norwegian colorectal cancer cases 
previously analyzed for TP53 mutations in their tumors were also included in this study 
(Børresen-Dale et al., 1998). DNA had been isolated from both blood cells and tumor tissue 
using chloroform/phenol extraction followed by ethanol precipitation (Nucleic Acid Extractor 
340A; Applied Biosystems) according to standard procedure (Børresen-Dale et al., 1998b).  
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METHODS 
Polymerase chain reaction 
The methods used in this thesis to detect mutations and polymorphisms are based on 
amplification of DNA by PCR. The PCR is an in vitro method for enzymatic synthesis of 
specific DNA sequences, using two oligonucleotide primers that hybridise to opposite strands 
and flank the region of interest in the target DNA. A cycle of denaturation, annealing 
(hybridisation of the primer), and extention (synthesis of the DNA fragment) is repeated until 
a certain amount of product has been produced (figure 21). The synthesis operates in the 3’-
end of the primer, towards the other primer, while the 5’-end defines the size of the fragment. 
During synthesis, a DNA polymerase connects the deoxyribonucleoside triphosphate 
molecules (dNTP) one by one at the growing 3’-end of the primer. The reaction takes place in 
a buffer to give the polymerase the best working conditions.  
In theory, only one single template is needed, therefore in performing PCR, one has to be 
particularly observant to problems concerning contamination. A negative control, without 
template DNA, is important to include in every run to exclude contamination. 
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Figure 21: An illustration of the 
polymerase chain reaction (PCR). 
(a) The solution is heated to 95°C to 
denature ("unzip") the two strands of 
the target DNA (b) The solution is 
cooled to ~55°C to allow the primers 
to anneal (bind) to the ends of the 
DNA strands (c) The solution is 
reheated to ~72°C to allow Taq 
polymerase to synthesize 
complementary copies of each 
strand (d-g) The cycle is repeated 
until a certain amount of product has 
been produced. The products of one 
cycle are used as template in the 
next cycle, giving an exponential 
growth of a given fragment. 20 cycles 
of PCR produces approximately one 
million (220) amplifications. 
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Heteroduplex analysis 
 
The methods used for identifying mutant ATM and TP53 alleles are based upon heteroduplex 
formation after PCR. The PCR product is heated to 95°C and slowly cooled to room 
temparature. The principle of heteroduplex formation is illustrated in figure 22 
 
 
       Figure 22: Principles of heteroduplex formation 
 
As a result of the heteroduplex formation caused by mutant alleles, the DNA will behave 
differently in an electrical field, temperature and chemical gradient. Thus, it becomes possible 
to separate mutant alleles from wildtype alleles when the DNA is submitted to varying 
conditions.  
 
 
DNA sequence analysis 
 
To determine the exact sequence of a mutation detected by heteroduplex analysis, DNA is 
sequenced in both directions using DyeDeoxy Terminator Cycle sequencing kits (Applied 
Biosystems) using an ABI 3100 DNA sequencer. In di-deoxy sequencing, DNA polymerase is 
put together with dNTPs in four different reactions, each containing a small amount of one di-
deoxy NTP (ATP, CTP, GTP or TTP).  The di-deoxy nucleotide lacks a 3'OH to continue 
chain extension, so the chain terminates.  Each reaction produces a population of fragments 
terminated at A, T, C, or G.  The fragments are labelled with fluorescent dyes and loaded in a 
capillary tube and subjected to electrophoresis i. Sequences of DNA in the gel lanes are read 
by a computerized fluorescence detection system that measures the intensity of light emission 
from each "band". The final output is a "trace" or "electrophoretogram" that plots the intensity 
                                                 
i Biology Dept Kenyon College http://biology.kenyon.edu/courses/biol114/Chap08/Chapter_08a.html Accessed 
1. Februrary 2005 
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of different color emissions vs. the length of the DNA being sequenced. By observing the 
progression of peaks of different colors, the DNA sequence is derived (A C G T). 
 
                                 
   Wild-type         Heterozygote             Homozygote 
 
Figure 23: An example of DNA sequencing results of the ATM gene, exon 24, codon 1082, 
showing the wildtype alleles, a heterozygote for the delATC insTGAT mutation, and a homozygote for 
the delATC insTGAT mutation. 
 
 
 
Screening for mutations in AT probands 
 
The Nordic and Norwegian AT family study has been ongoing for several years. Biological 
samples are continuously coming in and genetic analysis is performed consecutively. 
Therefore, different methods for mutation analysis, have been used over the years to detect 
mutations in the probands. The ATM gene has been screened for disease-causing mutations by 
heteroduplex analysis using DHPLC or protein truncating testing with subsequent sequence 
analysis at the cDNA and genomic level to identify the nature of the mutation.  
 
 
 
Denaturing High-Pressure Liquid Cromatgraphy (DHPLC) 
 
DHPLC is the most sensitive method for detecting mutations in the ATM gene so far 
(Bernstein, 2003). The wildtype allele and mutant allele are multiplied, heated and cooled to 
form heteroduplexes with mismatched basepairs and homoduplexes. The sample is injected 
into a flow path containing Acetonitrile (ACN)  and Triethylammonium Acetate (TEAA). It 
then passes through a cartridge with hydrophobic beads with temperature set for partially 
denaturing conditions. The hydrophopic portion of TEAA interacts with the hydrophobic 
beads in the cartridge, subsequently the negatively charged phosphate backbones of the 
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partially denatured DNA are attracted to the positively charged ammonium groups of the 
TEAA. At increasing concentrations of ACN the TEEA/DNA attraction is reduced and the 
fragments begin to elute off the cartridge. The heteroduplex with the mismatched base pairs 
elute off the cartridge first. The homoduplexes elute off the cartridge next. As the DNA 
fragments pass through an UV detector, absorbance is measured. The heteroduplex pass 
through first, then the homoduplexes. Data from the UV detector are sent to the computer for 
analysisj. X-axis represents time and peaks represent DNA fragments in figure 24. 
 
Figure 24: DHPLC screening of exon 24 for ATM mutations (top four graphs) and exon 39 
(bottom graph) for the most common polymorphism in the ATM – experiment conditions are 
optimalized in order to discover as many genetic variances as possible with the same settings. 
Cartridge temperature of this experiment was 58°C. Conditions have been described elsewhere 
(Bernstein et al., 2003). 
 
 
 
Protein truncation test 
 
The protein truncation test is designed to screen the coding region of a gene for mutations that 
cause premature termination of translation, large in frame deletions or insertions (reviewed in 
                                                 
j Transgenomics http://www.transgenomics.com Accessed 15. January 2005 
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Den Dunnen and Van Ommen, 1999). The principles of the PTT technique are outlined in 
figure 25. The PTT technique cannot detect epigenetic changes (like methylation), gross 
genomic alterations or minor changes not leading to truncated protein. 
 
 
Figure 25: Schematic presentation of the protein truncation test. First, RNA is reverse transcribed 
(RT) to generate a cDNA copy. Second, the cDNA (or genomic DNA) is amplified using the 
polymerase chain reaction (PCR) in combination with a specifically tailed forward primer facilitating in 
vitro transcription by T7-RNA polymerase. Products are analyzed on an agarose gel to verify 
amplification, determine yield, and check size; abnormally migrating products point to mutations 
(insertions, deletions, duplications, or affecting splicing). Finally, in vitro transcription/ translation is 
used to generate peptide fragments, analyzed on SDS-PAGE gel, to detect translation terminating 
mutations (Den Dunnen and Van Ommen, 1999). 
 
 
 
Identifying ATM mutation carriers in AT relatives 
 
Once the mutations on both alleles were identified in the proband and the maternal and 
paternal alleles were designated, mutation analysis of relatives was done by heteroduplex 
analysis of the known mutation in the corresponding parental branch by electrophoresis on a 
7,5 % polyacrylamid gel or by direct sequencing. The gel is stained with ethidium bromide 
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and then photographed using a Polaroid camera or a video based instrument (Gel Doc 1000, 
Bio Rad). 
 
The Norwegian founder mutation was detected by restriction enzyme cut, adding the enzyme 
HphI, with cutting site in exon 24, for 2 hours in 37°C, to the PCR product.  The mutant allele 
does not contain the restriction cut site and was separated from the digested wildtype allele in 
the electrophoresis as displayed in figure 26. 
 
 
Figure 26: Analysis by electrophoresis of DNA fragment from the ATM gene, exon 24, after 
restriction enzyme cut U=undigested; D=digested; M=size marker; bp=basepairs  
 
 
 
Detecting the TP53 Pro/Arg polymorphism 
 
 
Restriction fragment length polymorphism analysis 
 
The genetic variation in codon 72 in exon 4 of the TP53 gene was detected using Restriction 
Fragment Length Polymorphism analysis (RFLP) (Ara et al., 1990). The single-base change 
that causes an alteration of amino acid residue 72 from arginine to proline, was detected when 
the PCR product (119 p) was digested with BstUI for 3 hours at 60°C. The DNA fragments 
were separated by electrophoresis on a 4% agarose gel and gave an allele pattern of the two 
alleles of 113 bp + 86 bp (Arg) and 119 bp (Pro).  
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Statistical methods 
 
 
The Nordic and Norwegian AT study 
 
In the Nordic and the Norwegian study, the standardized incidence ratio (SIR) of cancer was 
calculated for carriers of an ATM mutation. National incidence rates for the tumour categories 
were calculated according to sex, age (in 5-year groups), and 5-year calendar periods and 
applied to the person-years of observation in the respective national subcohorts to obtain the 
number of cancers expected. In the Nordic study the observed and expected numbers of 
cancers, stratified by type of familial relationship and probability of carrying a mutation in the 
ATM gene, were pooled across country borders, and the SIRs were calculated. In the 
Norwegian study the observed and expected numbers of cancers in the individuals confirmed 
heterozygote were used to calculate SIRs. The 95% confidence intervals for the SIRs were 
calculated by assuming a Poisson distribution of the observed cancers.  
 
 
The Pro/Arg polymorphism in mutated TP53 
 
Cross-tabulation and χ2 test were performed when studying the polymorphism’s association 
with TP53 mutations. Pearson χ2 test or Fisher’s exact test (when appropriate) was used, and 
statistical significance level was set to P <0.05. Computations were performed using Excel 
and SPSS. 
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SUMMARY OF RESULTS 
 
 
Paper I 
 
The Norwegian AT families were characterized by pedigrees, through genealogical studies, 
by mutation analysis and calculation of the standardised incidence ratio of cancer for carriers 
of ATM mutations. Seven cancers occurred among the AT probands, 0,06 expected, yielding a 
standardized incidence ratio (SIR) of 119 (95% confidence interval (CI), 88-181). 168 blood 
relatives were analysed for the ATM mutation found in their family, an 85 were found to be 
heterozygotes. Among these carriers, 23 cancers were found (SIR 2.2; 95%CI 1.7-3.0). 
Invasive breast cancer was found in 6 cases (SIR 3.6; 95%CI 2.8-5.0), of whom 3 where 
mothers of probands. The SIR of breast cancer in females other than mothers of probands was 
2.2 (1.6-3.0). One Norwegian founder mutation accounted for 47% of disease causing alleles 
and there is a high degree of consanguinity in the Norwegian AT population. Carriers of the 
founder mutation had an elevated cancer risk for all sites, and the highest risk was for breast 
cancer in females.  When considering carriers of other mutations, a slightly higher risk of 
breast cancer and cancer at all sites was seen except an elevated risk of cancer at all sites in 
female, although this difference was not statistically significant. When DNA from both blood 
and tumour tissue from the same individual was analysed, some discrepancies were detected, 
possibly attributed to the genetic instability in many tumours resulting in loss of one allele.  
 
 
Paper II 
 
This study was an updated report on a previously published cohort study of cancer incidence 
in 1218 blood relatives of 56 Nordic AT patients from 50 families (Olsen et al, 2001). In this 
update, 1445 blood relatives, 75 patients in 66 families were included. The ATM mutation 
carrier probabilities of relatives were assigned from the combined information on location in 
family, consanguinity, if any, and supplementary carrier screening in some families (see paper 
I). Among the 1445 blood relatives of AT patients, 225 cancers were observed, with 170.4 
expected, yielding a standardized incidence ratio (SIR) of 1.3 (95% confidence interval (CI), 
1.1–1.4). Invasive breast cancer occurred in 34 female relatives (SIR, 1.7; 95% CI, 1.2–2.4) 
and was diagnosed in 21 women before the age of 55 (SIR, 2.9; 95% CI, 1.8–4.5) including 
seven mothers of probands (SIR, 8.1; 95% CI, 3.3–17). In the group of verified ATM 
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heterozygote females, the risk of breast cancer was 2.7 fold increased considering all age 
groups, and 5.2 fold increased in females below the age of 55.  When the group of mothers 
was excluded, no clear relationship was observed between the allocated mutation carrier 
probability of each family member and the extent of breast cancer risk. 
 
 
Paper III 
 
An Arg/Pro polymorphism in codon 72 of the TP53 gene was analyzed in blood samples from 
390 breast and 162 colorectal cancer patients previously investigated for TP53 mutations in 
their tumours. Among the breast cancer cases, 228 were homozygous for the Arg72 allele, of 
which, 65 (28.5%) also had a TP53 mutation in their tumours. In contrast, of the 26 cases that 
were homozygous for the Pro72 allele, only 1 case (3.8%) had a TP53 mutation in the tumour 
(P =0.004). Cloning the TP53 gene from tumour DNA followed by sequencing was 
performed in 14 heterozygotes with tumour mutation, and 9 of the mutations resided on the 
Arg72 allele. Among the colorectal cancer cases, no difference in mutation frequency was 
seen between the two different homozygotes, 40 TP53 mutations in 97 Arg72 homozygous 
cases (41.2%) versus 7 in 16 Pro72 homozygous cases (43.8%).  
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DISCUSSION OF RESULTS 
 
 
Cancer risk in ATM heterozygotes 
 
Pedigree analyses and mutation detection 
 
In the Norwegian AT population a founder mutation is responsible for 47% of the disease 
causing alleles; found in 11 of 18 families. A common attendant haplotype has been seen in 
all individuals carrying the mutation (Laake et al., 1998) and five of the families are 
demonstrated descendants of a couple born in the 15th-century. Most likely there are even 
more families attached to the “Rendal-pedigree”. In families as these, with a high degree of 
consanguinity and in the presence of a founder mutation, it is essential that epidemiological 
studies are combined with molecular studies and pedigree analyses. Estimation of carrier 
probability – especially background probability - would be inaccurate in these Norwegian AT 
families, since they have a much greater risk of being carriers than the rest of the population. 
Thus, without molecular analysis it is impossible to reveal a true correlation between carrier 
status and increased cancer risk.  
 
 
Breast cancer risk in females 
 
The risk of female breast cancer was 3.6-fold increased in the Norwegian study in all female 
relatives verified ATM heterozygous with a lower limit of the 95% confidence interval of 2.8. 
In the Nordic study, which included the Norwegian AT relatives, there was a 2.9-fold increase 
in the risk for breast cancer among all women under the age of 55 and a risk close to that of 
the general female population for women in the age group 55 years or more. In females 
verified ATM heterozygous the increased risk of breast cancer was 2.7-fold in all age groups, 
and 5.2-fold in females below the age of 55. Thus, the risk of breast cancer in all verified 
ATM heterozygote females was lower in the Nordic study than the lower limit of the 95% 
confidence interval found in the Norwegian study, suggesting that different mutations infer a 
different cancer risk. The Norwegian mutations are only found in two Nordic alleles outside 
of Norway.  
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In the Nordic study, the data did not convincingly point to a trend of increasing risk of breast 
cancer with each increment in the probability of being an ATM mutation carrier. The derived 
risk estimates on the potential role of ATM heterozygosity were to a large extent driven by the 
highly increased risk for breast cancer seen in mothers of probands. Other large studies of 
blood relatives of patients with AT (Janin et al, 1999; Inskip et al, 1999; Swift et al, 1991; 
Athma et al, 1996) have consistently shown an increased incidence or mortality (UK study) of 
breast cancer among female family members. The combined data from the published studies 
of breast cancer risk in female relatives of AT patients demonstrate a substantial and 
consistent increase in the risk for mothers. The existing international data on the risks for 
breast cancer of other female relatives are, however, still not conclusive, and convincing data 
to support a simple relationship between likelihood of ATM heterozygosity and risk of breast 
cancer has not yet been presented (see discussion in Paper II). In the Norwegian study, SIR of 
breast cancer in verified ATM heterozygote females other than mothers of probands was 
significantly 2.2-fold increased. However, this estimate is only based on the observation of 18 
heterozygote individuals. The discrepancy between the Norwegian and the Nordic study can 
be a result of inaccurate carrier estimates caused by a greater degree of consanguinity than 
anticipated in the Nordic study or that different mutations infer different cancer risks since 
Norwegian ATM alleles only recur in two alleles in another Nordic country. A recent study 
has suggested that truncating mutations in different domains of the ATM protein infer 
different cancer risks (Cavaciuti et al., 2005).  
 
An alternative hypothesis of a confined risk of breast cancer restricted to mothers of AT 
children, as presented in the absence of a gradient of breast cancer incidence by increasing 
probability of being a gene carrier, is that giving birth to an AT child or having a pregnancy 
with a foetus affected with AT affects the mother’s breast cancer risk - in combination with or 
regardless of any effect of her ATM heterozygosity. Microchimerism during pregnancy, i.e. 
the phenomenon that foetal cells may pass into the maternal circulation and tissues, might 
play a role in the highly increased risk of breast cancer seen among the mothers giving birth to 
an AT child. The presence of foetal AT cells in the circulation or tissues of the mother may 
contribute to the development of maternal breast cancer (see discussion Paper II).  
 
 66
Risk of cancers other than female breast 
 
The Nordic study found a slight increased risk for cancers at all sites excluding breast, which 
reached statistical significance for female relatives only. The Norwegian study, however, 
found significantly elevated SIRs of cancer at all sites for male, female and both sexes 
combined in the verified ATM heterozygote. No cancers were calculated independently in the 
Norwegian study other than breast, since the numbers were low. In the Nordic study there was 
a tendency for slight but non-significant elevations in risk for most cancer types. Especially, 
female relatives had excess numbers of cancers of the gall bladder and liver, which correlated 
with the mutation carrier probability of the subjects, but which was not replicated among male 
relatives. The slight increase seen for ovarian cancer was not correlated with mutation carrier 
probability or familial proximity to the proband; this was also the case for the increased risk 
for malignant melanoma in male relatives. A study done in the US has (Swift et al, 1991) 
reported a significant 2.5-fold increase in the risk for cancers at all sites combined in male 
relatives (73 observations) compared with that of spouses of female relatives (19 
observations), and a significant 3.9-fold increase in all cancers in male obligate heterozygote 
(18 observations). These findings concur with the findings in the Norwegian study: a 
significant 2.1-fold increased risk for cancer at all sites in males with an upper limit of the 
confidence interval of 3.9. A risk estimate for all cancers other than breast in female relatives 
was not made in the US study, but re-calculation on the basis of the data reported in the paper 
indicates that the risk was lower than that of male relatives. The Norwegian study support the 
findings that the risk of cancer in females other than breast (1.7 fold increased) is lower than 
the risk of cancer at all sites for males. In the Nordic study, there is no support for a 
substantially increased risk for cancers among male relatives. In a separate analysis of the 
incidence of cancers at sites other than the breast, the French study obtained an overall RR of 
0.9 for both sexes combined on the basis of 93 observations (Geoffroy-Perez et al, 2001). The 
differences reported between the different populations may be due to the type of ATM 
mutations occurring in these populations.  
 
Furthermore, in the Norwegian study, the individuals heterozygous for the Rendal-mutation 
and those with other types of mutations, had significantly elevated risks for males, females 
and both sexes combined of cancer at all sites for both groups. For both the carriers of the 
Rendal-mutation and carriers of other mutations, the highest risk was for breast cancer in 
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females. The risks of cancer at all sites and breast cancer in females, was non-significantly 
different in carriers of the Rendal-mutation than in carriers of other mutations. Thus, from the 
Norwegian study we cannot conclude that the Norwegian founder infers a different cancer 
risk than the other mutations found in the Norwegian population without further studies on 
larger cohorts. 
 
The main limitation of the Nordic and Norwegian studies, as well as other studies of cancer in 
AT families, is the small number of individuals included, and with associated low precision in 
risk estimation for site-specific cancers, including female breast cancer, ovarian cancer, 
lymphomas and leukaemias. There is a need for increased international collaboration in the 
study of cancer in AT families and, if feasible, a combined analysis of the available study 
materials. The hypothesis of breast cancer risk related to being pregnant with an AT-affected 
child also needs to be pursued. 
 
 
 
The Pro/Arg polymorphism in mutated TP53  
 
In our study there was an observed skewed occurrence of somatic TP53 mutations on the 
Arg72 allele in breast carcinomas suggesting that this combination gives breast epithelial cells 
a growth advantage, which may increase the risk of malignant transformation and 
development of cancer. However, in contrast to the breast cancer cases, no difference in the 
frequency of mutations between the Pro/Pro and Arg/Arg homozygote was found in colorectal 
cancer. The spectrum of TP53 mutations is different between these two tumour typesk, partly 
attributable to tissue-specific differences in carcinogen exposure and in metabolism (reviewed 
in Hainaut et al., 2000). The effect of coexistence of the Arg72 with a mutation may modify 
the TP53 protein structure in a way that interferes either with the protein’s ability to achieve 
sequence specific binding to DNA or with the interaction and recruitment of the transcription 
machinery, causing an altered transcription pattern (Campomenosi et al., 2001). Another 
possibility is that the Arg72 may modify the mutant TP53 protein’s ability to bind to and 
interact with other proteins such as, for example, TP73, (Di Como et al., 1999; Marin et al., 
2000), which may interfere with TP73-induced apoptosis. The same level of skewed 
                                                 
k The TP53 mutation database: www.iarc.fr/P53/index.html. Accessed 21. January 2005 
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distribution of mutations residing on the Arg72allele as seen for all type of mutations was also 
seen for missense mutations, giving no evidence for a stronger effect of such mutations. 
However, missense mutations are of many different types, and classifications according to 
structure or function in different cell types in larger series may give other results. The more 
severe changes like deletion, insertion, nonsense, and splice mutations may lead to a truncated 
protein or lack of protein where a codon 72 polymorphism has no modifying impact. 
Analyzing non-missense mutations as one group with respect to the codon 72 homozygotes 
gave no skewed distribution (P = 0.710). The number was, however small, and even truncated 
TP53 proteins may have an impact through mechanisms like inactivating other proteins (e.g., 
TP73) if their interacting domain is intact and the protein is stable. It cannot be excluded that 
the two polymorphic variants may have different effects also on such mutants.  
 
The effects of the Arg 72allele on mutant TP53, were associated with breast but not colon 
cancer development. A plausible explanation could be that the TP53 mutants in colon cancer 
are of a different nature than in breast cancers. TP53 mutants in colon cancer have been 
predicted to have a predominantly dominant negative effect on wildtype TP53, and it has been 
proposed that it is only the recessive mutations that are preferentially located on the Arg72 
allele. The dominant negative mutants have been suggested to be independent of the codon 72 
polymorphism (Tada et al., 2001). Tada et al. proposed criteria for classifying the mutations 
and when these criteria were applied to our series, the frequency of dominant negative 
mutants were higher in the colorectal cancer cases (83.3%, 30 of 36) than in the breast cancer 
cases (61.1%, 22 of 36; P =0.064). Although only a minor fraction of the mutants (72 of 175) 
could be classified according to these categories, these results nevertheless support the 
hypothesis that a tumourigenic effect of the Arg72 allele only occurs when combined with a 
somatic mutation of the type seen in breast carcinomas. Additional studies, including 
functional assays, are warranted to explore the effects of the different combined variants and 
their role in tumourigenesis in different tissues. 
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FUTURE PERSPECTIVES 
 
In the ATM heterozygotes, there is a need for further studies, in larger cohorts, to reveal the 
type of mutation and/or the location of the mutation that infers the greater cancer risk. 
Furthermore, analyses that enlighten the effect of specific mutations in ATM on cell and 
patient phenotype are needed. This can be used diagnostically for AT patients and their 
families.  
 
Analysing tumours, by whole genome approaches like expression profiling using microarrays, 
from carriers of ATM mutations will contribute to the understanding of the ATM gene in 
breast carcinogenesis. Further studies with emphasis on the TP53 gene are needed to elucidate 
whether there is an association with TP53 mutations in the tumour tissue and ATM 
heterozygosity and whether the Arg72 allele, found to be associated with TP53 mutations in 
breast cancer, plays a role in breast cancer carcinogenesis in ATM heterozygotes. Also, 
tumours from mothers of AT probands need to be analysed, to contribute to our understanding 
of the particular high risk of breast cancer in these mothers.   
 
Since AT is a rare disease, international collaboration is needed to be able to collect large 
enough cohorts of verified carriers to perform such studies.  
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Abstract 
Purpose: Epidemiological studies have consistently shown elevated rates of cancer, 
especially of the female breast, in blood relatives of patients with the rare autosomal, 
recessive disease, ataxia telangiectasia (AT). A large proportion of the members of AT 
families are carriers of AT-causing gene mutations found in the ATM gene. We here 
report pedigrees, molecular analysis and cancer incidence in 18 Norwegian AT-families 
including 20 probands and 168 blood relatives.  
Material and methods: Blood relatives of patients with verified AT were identified 
through population registry linkages, and the occurrence of cancer was determined 
from the cancer registry files in Norway and compared with national incidence rates.  
DNA was isolated from blood or tumour tissue of AT children and their relatives. DNA 
from the AT patients or their parents was screened for ATM germ-line mutations by 
protein truncation test and/or heteroduplex analysis using DHPLC followed by 
sequencing to determine the nature of the mutation. DNA from the more distant 
relatives was analysed for the respective mutation segregating in that branch of the 
family. 
Results: Seven cancers occurred amond the AT probands, 0,06 expected, yielding a 
standardized incidence ratio (SIR) of 119 (95% confidence interval (CI), 88-181). Of the 
168 blood relatives tested, 85 were found heterozygous for ATM mutations. 23 cancers 
were found among these individuals, (SIR 2.2; 95%CI 1.7-3.0). Invasive breast cancer 
was found in 6 cases (SIR 3.6; 95%CI 2.8-5.0), of whom 3 where mothers of probands. 
One Norwegian founder mutation accounted for 47% of disease causing alleles and 
there is a high degree of consanguinity in the Norwegian AT population. Carriers of the 
founder mutation separated from carriers of other mutations had an elevated cancer 
risk for all sites, and the highest risk was for breast cancer in females. Considering 
carriers for other mutations, a slightly higher cancer risk was seen in these individuals, 
other than female cancer at all sites, although this was not statistically significant.   
When DNA from both blood and tumour were analysed for the same individuals, some 
discrepancies were detected and possibly attributed to the genetic instability in many 
tumours.  
Conclusion: This study has confirmed that an individual heterozygote for ATM 
mutation has an increased risk of cancer at all sites and females particularly of the 
breast. No conclusive findings were made suggesting that the Norwegian founder infers 
 3
a different cancer risk than other mutations. Epidemiological studies need to be 
supported not only by accurate pedigrees of the families, but by molecular analysis as 
well, especially when there is consanguinity. In these families, statistically calculated 
carrier risk would be inaccurate without this information. Furthermore, blood samples 
are the reliable source of genetic information and are needed for accurate analysis of 
carrier status of the ATM gene. 
 
 
Introduction 
The rare autosomal recessive disease ataxia telangiectasia is caused by mutations in the ATM 
gene. Mutations leading to the classical AT phenotype, with progressive cerebellar ataxia, 
telangiectasia of the eyes, immunodeficiency, elevated alpha-feto protein levels, chromosomal 
instability and a susceptibility to develop leukemia and cancers of lymphoid origin are to a 
large degree truncating mutations. (Gatti et al., 1991)  Other mutation types in the ATM gene 
such as missense mutations have also been found, leading to an AT like disease in the 
homozygous state or in compound heterozygous for a mild and a severe mutation, usually to a 
milder phenotype (Gilad et al., 1998). The estimated carrier frequencies in the general 
population is in the order of 0.5–1% for an AT-causing mutation. A heterozygous individual 
shows no symptoms of AT, however several studies have reported that relatives of AT 
patients are at three- to fivefold increased risk of developing breast cancer (Swift et al., 1991; 
Geoffrey-Perez et al., 2001; Olsen et al., 2001) and perhaps other cancers. Molecular studies 
of breast cancer patients have failed to detect an increased frequency of potentially AT-
causing mutations in breast cancer (Vorechovsky et al., 1996a Vorechovsky et al., 1996b; 
Chen et al., 1998) However, it has been hypothesized that “milder” mutations leading to 
conservative amino acid changes, inhabit a greater cancer risk in the heterozygote state than 
truncating mutations. This is due to a possible dominant negative effect of mutated ATM on 
the wildtype ATM when the mutated ATM is not truncated (Scott et al., 2002). Truncated 
protein is most commonly rapidly degraded by proteases. When this does not occur, as in the 
case of many missense mutations, mutated ATM will form dimers or multimers with wildtype 
ATM inhibiting the functional properties of the wildtype protein (Chenevix-Trench et al., 
2002). No significant correlation between mutation type and increased cancer incidence has 
been found so far in the AT families. However, it has been suggested that truncating 
mutations in domains particularly involving TP53 binding, lead to an increased cancer risk 
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(Cavaciuti et al., 2005). Thus, the question is if both the type and location of mutation in the 
ATM gene might have a significant impact upon cancer risk.  
A Norwegian founder mutation in exon 24 (Laake et al., 1998), causing 12 amino acid 
substitutions and truncation of the protein, has previously been reported to be responsible for 
55% of the Norwegian disease causing alleles (Laake et al., 1998). Epidemiological studies in 
the Nordic countries have previously reported an increased cancer risk for heterozygotes in 
this population (Olsen et al., 2000 and Olsen et al., submitted). However, there is a high 
degree of consanguinity in the Norwegian population, which makes statistical evaluation of 
carrier status inaccurate. Also, because of the high incidence of the Norwegian founder 
mutation it is possible to statistically estimate whether individuals with truncating mutations 
in this specific location have an increased cancer risk compared to other mutations found in 
Norwegian AT families. Here, we present pedigrees of the Norwegian AT families, their ATM 
mutation carrier status based on molecular analysis and calculated cancer risks for ATM 
heterozygous individuals.  
 
Materials and methods 
A total of 18 families of Norwegian origin were studied. All diagnoses were made on the 
basis of internationally recognized clinical and laboratory criteria obtained from the medical 
records of the patients. Absolute criterion for inclusion was progressive cerebellar ataxia. 
Supporting criteria were telangiectasias, ocular apraxia, dysarthria, history of infections 
(minimum one episode of pneumonia), elevated alpha-feto-protein, chromosome 
rearrangements involving chromosomes 7 and 14, and/or increased chromosome breakage and 
decreased IgA or IgG2. Informed consents were gathered through the Norwegian study 
coordinator and the immediate family of probands. One family chose not to participate 
(NOAT12). Blood samples, lymphoblastoid cell lines, fibroblasts and tumour tissue from AT 
probands and their relatives were collected from all cases verified or suspected AT and the 
families were included as the diagnoses were verified. One family was excluded on this basis. 
(NOAT19). All of the cancers were confirmed by the Norwegian cancer registry and/or by 
other pathologists. The malignant neoplasms identified in the cohort of relatives were 
classified according to the International Classification of Diseases, 7th Revision. The 
registration and coding practices of the cancer registry has been described elsewhere (Tulinius 
et al, 1992).  
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Mutation analysis  
Several mutation analysis techniques have been used to locate the disease causing ATM 
mutation in AT probands as the Norwegian AT study has been ongoing for over a decade. 
DGGE (denaturing gel gradient electrophoresis, described in Børresen et al., 1998) has a high 
sensitivity for detecting the Rendal-mutation, however, sensitivity for other mutations than the 
Rendal is low (Laake et al., 1998). With the PTT (Protein Truncation Test, reviewed in Den 
Dunnen and Van Ommen, 1999) we detected other mutations that cause premature 
termination of translation or large in frame deletions (Telatar  et al., 1998 and Laake et al., 
2000). Heteroduplex analysis by DHPLC (denaturing high pressure liquid chromatography) 
has proven the most sensitive and mutations are found where the older techniques failed to 
detect mutations  (conditions described in Bernstein et al., 2003 and method reviewed in Xiao 
and Oefner, 2001) Thus, screening for ATM germline mutations has been done on DNA from 
the AT patients or their parents by protein truncation test and/or heteroduplex analysis using 
DHPLC. When a variant pattern was observed by DGGE, PTT or DHPLC the DNA or 
cDNA, was sequenced in both directions using DyeDeoxy Terminator Cycle sequencing kits 
(Applied Biosystems, Inc., Foster City, CA) using an ABI 3100 DNA sequencer (Applied 
Biosystems, Inc).   
When the probands mutations were identified, their blood relatives were analysed with 
heteroduplex analysis or direct sequencing on DNA extracted from blood samples or paraffin 
embedded tumour tissue (protocol described in appendix).  
 
Statistical analysis  
The standardized incidence ratio (SIR) of cancer was calculated for carriers of an ATM 
mutation. National incidence rates for the tumour categories were calculated according to sex, 
age (in 5-year groups), and 5-year calendar periods and applied to the person-years of 
observation in the respective national subcohorts to obtain the number of cancers expected. 
The observed and expected numbers of cancers in the individuals confirmed heterozygote 
were used to calculate SIRs. The 95% confidence intervals for the SIRs were calculated by 
assuming a Poisson distribution of the observed cancers. Statistical calculations were made 
using SPSS, version 11.5, and Excel 2000. 
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Results 
Screening for the ATM mutations in the AT probands 
A total of 20 AT patients in 18 Norwegian families were included in the study. Nine probands 
were alive as of 311202, and the oldest Norwegian proband reported, died at age 33. The 
patients were born in the period 1962-2002. The diagnosis of the proband is supported by 
identification of a disease causing mutation in the ATM gene in both alleles in 17 families. In 
one family only one disease causing allele has been found. Previous linkage studies have 
concluded that the other mutation is a de novo mutation (Laake et al., 1998), however it has 
yet to be found (the patient has died and there is no more DNA). Table 1 shows the 
distributions of mutations and the expected consequences for the protein. 12 unique disease-
causing mutations are found in the Norwegian families (of which three are not previously 
published) Three, previously reported mutations were found in new families. The mutations 
found in the Norwegian AT families have different consequences for the ATM protein: 74 % 
(26/35) of the parental branches have frameshift mutations that subsequently lead to 
truncation of the protein, 14 % (5/35) have splice site mutations that lead to skipping of 
exons, 6 % (2/35) have nonsense mutations, inducing stop codons at the mutation site, 3% 
(1/35) have double substitutions and 3 % (1/35) have missense mutations. With this low 
fraction of mutations with “mild” consequences for the protein, we chose not to make 
statistical calculations of SIR segregating for different type of mutations. 
 
 
Pedigree analyses and mutation status detection  
A previously identified founder mutation in exon 24 (Laake et al., 1998) which changes the 
sequence from ATC to TGAT inducing a stop codon thirteen amino acids downstream, was 
found in 11 out of the 18 families, in 18 out of 39 found proband alleles (46%) Seven patients 
were homozygotes for this so-called “Rendal-mutation” and four patients were compound 
heterozygous. Geneological studies have so far identified a common ancestor for 5 of the 
Norwegian AT families with the founder mutation (28 %). The common ancestor was born in 
approximately 1495. Figure 1 shows how the families are connected. Further genealogical 
studies would most likely reveal that even more Norwegian AT families are of common 
descent since the allele is so frequent in the Norwegian AT probands.  
 
In addition to the large pedigree for the Norwegian founder mutation, pedigrees were made of 
all the Norwegian AT families. The pedigrees in figure 2 contain ATM carrier status for those 
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tested, cancer diagnosis and age at time of diagnosis. The pedigrees were made in order to 
trace the disease causing mutation and discover consanguinity. The presence of consanguinity 
found in the Norwegian population affects carrier probabilities, and thus, carrier probabilities 
will be inaccurate without knowing the extended pedigree and the intermarriages that have 
occurred over time.  
The father in family NOAT 7 and mother in NOAT 8 carry the same mutation and haplotype 
(Laake et al., 1998). They were born in the same community. The mother in NOAT 7 carries 
the same mutation found in both parents in family NOAT 13 where the parents probably have 
common ancestors. The maternal and paternal grandfathers carry the same mutation. In two 
families, two siblings were affected. (Laake et al., 2000) 
 
A total of five mutations recur in the Norwegian families. Six of the mutations are also found 
outside of Norway, 2 in Denmark (1 allele of each), 3 in the US (1 allele of each), 1 in the 
Netherlands (3 alleles) and one in Great Britain (1 allele) (Telatar et al., 1998; Laake et al., 
1998; Li and Swift, 2000, van Belzen et al., 1998; Stankovic et al., 1998; Teraoka et al., 1999 
and Laake et al., 2000).  
 
Gene testing for the family mutation was conducted for a total of 168 blood relatives of AT 
probands from all 18 families. DNA from these relatives was analysed for the respective 
mutation segregating in their branch of the family (table 2). 140 analyses were done on the 
basis of a blood sample from a live relative and 28 solely on the basis of tissue from an 
archival tumour block. When possible, DNA from both normal and tumour tissue was 
extracted from the paraffin block. For 13 individuals both blood and tissue samples were 
available for analysis. In three of the heterozygote cases, the results from the analysis of DNA 
from the tumour block did not correspond with blood result. Only the wildtype allele was 
found, indicating a loss of the mutated allele.  
 
Cancer risk 
A total of 7 cancers occurred among the AT probands and 23 cancers in the ATM 
heterozygous. One AT proband and four heterozygous individuals had two primary cancers 
originating at different sites. Thus, in the probands, 7 cancers were observed with 0,06 
expected, yielding a SIR of cancer at all sites of 119 for both sexes with 95% confidence 
interval of 88-91 (table 3). It was lower for males, with a 45-fold increased risk of cancer (33-
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73) and higher for females, 163-fold increased risk (105-359). The cancers were lymphomas 
and leukemias, except for one liver cancer.  
 
In the mutation verified heterozygous individuals 23 cancers were observed, with 10,7 
expected, yielding a 2.2-fold increased risk of cancer at all sites (95%CI 1.7-3.0) (table 4). In 
females 6 breast cancers were observed and 1,7 expected, SIR 3.6 (2.8-5.0). Three of the 
breast cancers were in mothers of a proband. If the mothers were excluded, risk of breast 
cancer for females was 2.2 (1.6-3.0). For female cancer other than breast the SIR for all 
females was 1.7 (1.2-2.6).   
 
When separating the heterozygous into two groups, one with the founder mutation and the 
other group with mutations different than the founder, observed cancers in both sexes with the 
founder mutation were 13 and expected 6,3, SIR 2.1 (1.5-3.4). Females with the founder had 
an SIR of breast cancer of 3.0 (2.2-5.0).  In the group with mutations different from the 
founder, in both sexes 10 cancers were observed, with 4,4 expected, SIR 2.3 (1.7-3.5). 
Females with other mutations than the founder had a SIR of breast cancer of 4.3 (3.0-8.1). 
 
 
Discussion 
In families with a high degree of consanguinity and especially in the presence of a founder 
mutation, it is essential that epidemiological studies are combined with molecular studies and 
pedigree analyses. Five of the families carrying the founder mutations have been linked 
together, but most likely there are even more families attached to the “Rendal-pedigree”. 
Thus, any estimation of carrier probability – especially background probability - would be 
inaccurate in several of the Norwegian AT families, since they have a much greater risk of 
being carriers than the rest of the population due to consanguinity. In other words, without 
molecular analysis it is impossible to reveal a true correlation between carrier status and 
increased cancer risk.  
 
The ATM heterozygous have significantly elevated SIRs of cancer at all sites for male, female 
and both sexes combined. The risk of female breast cancer is the most elevated cancer type, 
significantly higher than other female cancers, which is also elevated. When we divide the 
heterozygous into two groups, those carrying the Rendal-mutation and those with other types 
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of mutations, we find significantly elevated risks for males, females and both sexes combined 
of cancer at all sites for both groups. For both the carriers of the Rendal-mutation and carriers 
of other mutations, the highest risk was for breast cancer in females. The risks of cancer at all 
sites and breast cancer in females, was non-significantly different in carriers of the Rendal-
mutation than in carriers of other mutations. Thus, we cannot conclude that the Norwegian 
founder infers a different cancer risk than the other mutations found in the Norwegian 
population without further studies on larger cohorts.  
 
The risk of female breast cancer was 3.6-fold increased in the Norwegian study in all female 
relatives verified ATM heterozygous with a lower limit of the 95% confidence interval of 2.8. 
In a Nordic study (Olsen, submitted), which includes the Norwegian AT relatives, there was a 
2.9-fold increase in the risk for breast cancer among all women under the age of 55 and a risk 
close to that of the general female population for women in the age group 55 years or more. In 
females verified ATM heterozygous the increased risk of breast cancer was 2.7-fold in all age 
groups, and 5.2-fold in females below the age of 55. Thus, the risk of breast cancer in all 
verified ATM heterozygote females was lower in the Nordic study than the lower limit of the 
95% confidence interval found in the Norwegian study, suggesting that different mutations 
infer a different cancer risk as suggested by others (Caviacuti  et al., 2005).  The Norwegian 
mutations are only found in two Nordic alleles outside of Norway.  
 
When tumour samples are collected, more heterozygous individuals with tumours will be 
detected than heterozygous without tumours. As well, individuals with cancer might be more 
interested in and available for giving blood samples than healthy individuals. This is a source 
of selection bias in all studies were complete ascertainment is not possible. 
 
The discrepancy seen between the results from blood DNA and tumour DNA from the same 
individual is possibly due to a loss of heterozygosity in tumour tissue. If one allele is lost this 
would not give heteroduplex formation during PCR and the sample will be interpreted as a 
wildtype.  
 
More than one block was available from tumours for several individuals. In three individuals, 
the analysis done on different blocks gave different results. Both normal tissue and tumour 
tissue from the blocks were analysed, and the results differed for both normal and tumour 
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tissue. These individuals were excluded from the study, as we had no conclusive mutation 
status data. To explain these findings we attribute this to both tumour hetereogeneity and the 
early occurrence of LOH in some cancers, which might affect adjacent, hyperplastic tissue 
(Chin et al., 2004). The ATM gene does not seem to follow the classical Knudson two hit 
modell for tumour suppressors. The mutated ATM allele, not the healthy allele, is lost in some 
of these tumours due to genetic instability. In mutation analysis based on heteroduplex 
formation, blood samples are the only reliable source of information on carrier status and 
blood samples should be taken from everybody.  
 
 
Conclusion 
This study has confirmed that an individual heterozygote for ATM mutation has an increased 
risk of cancer at all sites and females particularly of the breast. No conclusive findings were 
made suggesting that the Norwegian founder confers a different cancer risk than other 
mutations. Epidemiological studies need to be supported not only by accurate pedigrees of the 
families, but by molecular analysis as well, when there is consanguinity. In these families, 
statistically calculated carrier risk is inaccurate without this information. To further 
investigate whether different mutations actually infer different cancer risks and to what 
degree, mutation analysis of all participants and pooling of international cohorts are needed. 
Furthermore, blood samples are the reliable source of genetic information and are needed for 
accurate analysis of carrier status of the ATM gene. 
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ABSTRACT 
Epidemiological studies have consistently shown elevated rates of breast cancer among female 
blood relatives of patients with ataxia telangiectasia (AT), a rare autosomal recessive disease. A 
large proportion of the members of AT families are carriers of AT-causing gene mutations in ATM 
(Ataxia Telangiectasia Mutated), and it has been hypothesized that these otherwise healthy carriers 
are predisposed to breast cancer. Blood relatives of patients with verified AT in the Nordic 
countries were identified through population registry linkages, and the occurrence of cancer was 
determined from cancer registry files in each country and compared with national incidence rates. 
The ATM mutation carrier probabilities of relatives were assigned from the combined information 
on location in family, consanguinity, if any, and supplementary carrier screening in some families. 
Among the 1445 blood relatives of AT patients, 225 cancers were observed, with 170.4 expected, 
yielding a standardized incidence ratio (SIR) of 1.3 (95% confidence interval (CI), 1.1–1.4). 
Invasive breast cancer occurred in 34 female relatives (SIR, 1.7; 95% CI, 1.2–2.4) and was 
diagnosed in 21 women before the age of 55 (SIR, 2.9; 95% CI, 1.8–4.5) including seven mothers 
of probands (SIR, 8.1; 95% CI, 3.3–17). When the group of mothers was excluded, no clear 
relationship was observed between the allocated mutation carrier probability of each family member 
and the extent of breast cancer risk. We concluded that the increased risk for female breast cancer 
seen in 66 Nordic AT families appeared to be restricted to women under the age of 55 and was due 
mainly to a very high risk in the group of mothers. The findings of breast cancer risk in mothers, but 
not other likely mutation carriers, in this and other studies raises questions about the hypothesis of a 
simple causal relationship with ATM heterozygosity.  
 
Key words: ATM heterozygosity; early-onset breast cancer; cancer predisposition; familial cancer 
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INTRODUCTION 
While mutations of both alleles of the ATM (Ataxia Telangiectasia Mutated) gene cause the rare 
autosomal recessive disorder ataxia telangiectasia (AT), heterozygous carriers of an ATM allele are 
healthy. Several studies, however, have estimated carriers to be at three- to fivefold increased risk 
for developing breast cancer (Swift et al, 1991; Athma et al, 1996; Inskip et al, 1999; Janin et al, 
1999; Geoffroy-Perez et al, 2001; Olsen et al, 2001) and perhaps other cancers. With calculated 
mutation carrier frequencies in the general population in the order of 0.5–1% for ATM gene 
mutations, ATM heterozygosity might be responsible for a sizeable proportion of breast cancers in 
the (female) population (Easton, 1994).  
We previously published a cohort study of cancer incidence in 1218 blood relatives of 56 Nordic 
AT patients from 50 families (Olsen et al, 2001). In order to increase the statistical power of the 
study, we added 16 more families, and 227 relatives. We extended the follow-up for cancer 
incidence and a further correction of the mutation carrier probabilities based on supplementary 
mutation carrier testing of relevant members in some of the families. The results of this updated 
study are reported here. 
 
MATERIALS AND METHODS 
In each of the participating countries (Denmark, Finland; Norway and Sweden), paediatric 
neurologists, paediatric immunologists, medical geneticists, cytogenetic laboratories and institutions 
for disabled children were requested to report cases of verified or suspected AT (from 1950 through 
2002) to the country’s study coordinator. The medical records were reviewed with respect to 
absolute and supporting criteria for the clinical diagnosis AT, as previously described (Olsen et al, 
2001). Blood samples, lymphoblastoid cell lines or fibroblasts were available for most families, 
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either from the proband (or affected siblings) when alive or from the parents. The ATM gene was 
screened for disease-causing mutations by heteroduplex analysis using DHPLC or protein 
truncating testing with subsequent sequence analysis at the cDNA and genomic level to identify the 
nature of the mutation (Laake et al, 2000; Bernstein et al, 2003). When biological samples were not 
available, the diagnosis of AT was based on the clinical and laboratory criteria. 
Tracing of relatives for construction of pedigrees was based on data from the computerized national 
civil registration systems of the Nordic countries, as these systems make use of the personal 
identification number (PIN), unique for each citizen, allowing accurate linkage of registry 
information on parents and their offspring. These registration systems were started in 1960 in 
Norway, 1961 in Sweden, 1967 in Finland and 1968 in Denmark, when the PIN was assigned to all 
citizens alive at that date; for individuals born after that date, the PIN is assigned at birth. 
Information on more distant ancestors was derived from manual local population and church 
registers. Finally, follow-up information on date of death or emigration of blood relatives was 
obtained from the aforementioned national civil registration systems and from the national mortality 
files. Additional details are given in the previous publication (Olsen et al, 2001). 
Data on blood relatives of AT patients were linked to the national cancer registry of the respective 
Nordic country by the subjects’ PIN or, if they had died before the civil registration systems were 
computerized, their date of birth, date of death and name (Olsen et al, 1993). The period of follow-
up for the occurrence of cancer among siblings, cousins, uncles, aunts and grandparents’ siblings 
extended from the date of birth or the inception of national cancer registration (Denmark, 1943; 
Norway, 1953; Finland, 1953; Sweden, 1958), whichever came later, to the date of death or 
emigration or the end of study (31 December 2000 in Finland and Sweden and 31 December 2002 
in Denmark and Norway), whichever came first. Similar rules were applied to the parents, 
grandparents and great-grandparents of the AT patients, except that follow-up was started at the 
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earliest from the date of birth of the individual who was in direct line to the proband (e.g. the date of 
birth of the parent of the proband for grandparents). The malignant neoplasms identified in the 
cohort of relatives were classified according to the International Classification of Diseases, 7th 
Revision. The registration and coding practices of the four cancer registries have been described 
elsewhere (Tulinius et al, 1992). 
 
Statistical analysis 
The expected numbers of cancers were calculated by multiplying the number of person-years of 
family members by the national cancer incidence rates for men and women in 5-year age groups 
and calendar periods of observation. Observed and expected numbers of cancers were pooled 
among countries, and standardized incidence ratios (SIRs), taken as the ratio of observed-to-
expected cancers, were determined. The 95% confidence intervals (CIs) of the SIRs were calculated 
assuming a Poisson distribution of the observed cancers (Bailar and Federer, 1964).  
Cancer risk analyses were also undertaken after stratifying the study population according to their 
estimated gene carrier probability (1.0, 0.67, 0.5, 0.25, background). The individually assigned and 
estimated probability was the product of the location of the particular relative in the family pedigree 
(taking into account any information on consanguinity in the family) and the outcomes of any gene 
testing performed on members of the family, in addition to that already conducted on the proband, 
affected siblings and/or parents. For instance, if a grandmother tested positive for the one of the 
mutations of the proband, this changed the likelihood that the grandmothers’ and the grandfathers’ 
ancestors had been mutation carriers. In order to avoid bias due to selective testing of survivors in 
the families, however, the mutation carrier probability of the tested relatives themselves (which 
often was conducted years after the entry of the relative into the study cohort) were kept unchanged 
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in the risk analyses. The number of actual mutation carriers was estimated by multiplying the 
probability of being a carrier by the number of subjects in each subgroup of female relatives. On 
this basis, the relative risk for female breast cancer associated with heterozygosity for ATM 
mutation was estimated assuming that the excess risk for breast cancer observed in the entire group 
of female relatives can be ascribed to the subgroup of mutation carriers only (Olsen et al, 2001). 
 
RESULTS 
A total of 75 AT patients from 66 families (24 patients from 21 families in Denmark, six patients 
from six families in Finland, 21 patients from 19 families in Norway and 24 patients from 20 
families in Sweden) were included in the study. In nine families, two siblings were affected. The 
patients were born in the period 1949–2002 and all had a diagnosis of AT on the basis of clinical 
and laboratory findings. Biological material was available from the proband, an affected sibling 
and/or the parent(s) in 54 of the families representing 62 AT patients. A disease-causing mutation of 
the ATM gene was identified in both alleles in 57 patients from 50 of these families, while in five 
patients from four families material was available from only one parent, and therefore only one 
mutation was identified. In the remaining 13 patients from 12 families, biological material was not 
available, and the diagnosis was based entirely on clinical and laboratory information from the 
medical records. In two patients (from different families) who had both their mutations identified, 
the mutation of the maternal allele was shown to be de novo. Consequently, in the risk analyses 
stratified by carrier status these mothers and their ancestors were regarded carriers of a wild type 
AT allele. The pedigrees indicated consanguinity in eight (12%) of the 66 families (mainly cousin–
cousin marriages); however, homozygosity in the proband for a specific mutation was seen in 19 
(38%) of the 50 families for which full allelic information was available. Of these, seven were a 
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specific Norwegian founder mutation, the so-called Rendal mutation, located in exon 24 
(3245delATCinsTGAT) (Laake et al, 2000). 
In addition to gene testing of affected siblings and parents of probands, testing was conducted for 
37 relatives from 13 Norwegian families: 21 on the basis of a blood sample from a live relative and 
16 on the basis of tissue from a paraffin embedded tumour block from a deceased relative. This 
increased the number of obligate carriers (from 144 to 152) as well as the numbers of relatives with 
gene carrier probabilities of 0.5 (from 441 to 459) and ‘background’ (from 42 to 136). On the 
contrary, it reduced the numbers of relatives with gene carrier probabilities of 0.67 (from 75 to 73) 
and 0.25 (from 873 to 755).  
Of the 1575 unaffected blood relatives successfully identified, 130 had died before the date of 
eligibility, leaving 1445 relatives for cancer risk analysis. These consisted of 733 men and 712 
women; 128 parents, 84 siblings, 189 grandparents, 241 uncles and aunts, 400 cousins, 170 great-
grandparents and 233 grandparents’ siblings. The entire group represented some 46 000 person-
years of follow-up (mean, 31.7 years; range, 0–60 years), during which time 225 cancers were 
observed (106 in men and 119 in women), with 170.41 expected, yielding statistically significant 
SIRs of 1.28 (95% CI, 1.1–1.4) overall, 1.15 (0.9–1.4) for men and 1.42 (1.2–1.7) for women.  
Of the 119 cancers in women, 34 were of the breast (all unilateral), with 19.51 expected, yielding a 
statistically significant SIR of 1.7 (Table 1). The association with breast cancer was particularly 
strong in the group of 64 mothers (the mother was missing in each of two Swedish families), who a 
priori were assumed to be ATM mutation carriers, although genetic testing revealed that two was 
not (SIR of 6.7 and a lower limit of the 95% CI of 2.9). In the remaining, combined group of female 
relatives, the SIR for breast cancer was a modest 1.4 and non-significantly increased, although with 
an indication of an excess risk for grandmothers, grandmothers’ sisters and great-grandmothers. 
Table 1 also shows the risk for breast cancer according to estimated mutation carrier probability. 
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Among the ten women (mostly grandmothers) deemed to be mutation carriers by virtue of pedigree 
position or genetic testing, in addition to the 62 mothers being obligate carriers, there were no cases 
of breast cancers, decreasing the overall SIR of obligate carriers to 4.4, which still represents a 
significant risk elevation. The combined group of likely mutation carriers (probabilities of 0.67, 
0.50 and 0.25) had a marginally significant, modest 60% increase in the risk for breast cancer, but 
no increase in risk with higher likelihood of being a mutation carrier (Table 1). On the basis of the 
carrier probability distribution given in the lower part of Table 1, 287 of the 712 female relatives 
included in the analysis were estimated to be ATM mutation carriers, i.e. 40%. Assuming the 
existence of a true link between a mutated ATM allele and breast cancer, our data indicate that 
ATM heterozygosity on average infers a 2.9-fold (95% CI, 1.9-4.4) increase in the risk for female 
breast cancer. 
Of the 34 cases of breast cancers among women, 21 were diagnosed before the age of 55 years 
(SIR, 2.9) and 13 at the age of 55 or older (SIR, 1.1), suggesting the occurrence of early-onset 
breast cancer in these families (Table 2). Again, the association was clearly strongest for the 
mothers, with an 8.1-fold increase in risk in the age range below 55 years and a 3.3-fold increase as 
the lower 95% CI. Significantly increased risks were also seen for grandmothers, grandmothers’ 
sisters and great-grandmothers when data were available for that age range. Nevertheless, detailed 
data on risk elevation by mutation carrier probability did not reflect an increasing risk with higher 
likelihood of being a carrier (Table 2).  
No cases of breast cancer were observed among male relatives (0.1 expected). 
When we analysed the risk for breast cancer by selected characteristics of the probands and the 
families, we did not observe any tendency to higher risks for breast cancer among female relatives, 
including mothers, in the eight reported consanguineous families (SIR, 1.8), in the 19 families with 
probands homozygous for a mutation (SIR, 1.3), including the seven with Rendal mutation (1.5), or 
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in the nine families of probands with cancer (1.8), than we did among female relatives of the 
remaining groups of families, yielding SIRs of 1.8, 1.9, 1.8, and 1.7, respectively. Among the nine 
mothers with two affected offspring, one case of breast cancer was observed (SIR, 4.3), and among 
the remaining mothers with one affected child, seven cases were observed (SIR, 7.2). 
A total of 191 cancers were observed at sites other than the breast (106 in men and 85 in women) in 
the combined group of relatives, yielding a SIR of 1.2 (Table 3). The slightly but significantly 
increased overall risk was significant in women (SIR, 1.3) but not in men (1.2). As seen from the 
table, there was a tendency for increased risks for cancers at most sites, but malignant melanoma of 
the skin was the only site for which the increase reached statistical significance. The excess was 
seen primarily in men, but with no correlation to their likelihood of being mutation carriers; three of 
the 10 cases were seen in the subgroup with ‘background’ mutation carrier probability, when 0.6 
was expected.  
Because of the known genetic link between cancers of the breast and ovary, we reviewed family 
details for the eight AT family members with cancer of the ovary (SIR, 1.7). Two cases occurred in 
aunts, three in grandmothers and three in grandmothers’ sisters, but no case occurred in mothers. 
There was no indication of an increased risk with higher likelihood of being a mutation carrier. Of 
eight cases of cancers of the liver and biliary passages, six were observed in women, yielding a 
significantly increased SIR of 3.9; of these, three were in the mutation carrier probability group 1 
(0.08 expected; SIR, 36; 95% CI, 7.3–106), none in probability group 0.67/0.5 (0.5 expected), two 
in probability group 0.25 (0.8 expected), and one in probability group ‘background’ (0.2 expected). 
Two cases were seen in men (one in probability group 1 and one in group 0.50) when 0.8 was 
expected.  
In contrast to the findings for breast cancer, the tendency to increased risks for cancers at other sites 
was not further strengthened when the analysis was restricted to persons aged below 55 years. 
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DISCUSSION  
In this extended and enlarged follow-up study of cancer incidence in 1445 blood relatives of 75 
patients with AT, we observed a statistically significant, 2.9-fold increase in the risk for breast 
cancer among women under the age of 55 and a risk close to that of the general female population 
for women in the age group 55 years or more. Our observation of an increased risk for early-onset 
breast cancer, now on the basis of 21 observed cases, corroborates the finding of our initial follow-
up study, which was based on 13 cases (Olsen et al, 2001). The excess risk for breast cancer was 
evident in the mothers of the probands but less conspicuous in other female relatives, even those 
aged below 55. Although ATM heterozygosity in relatives on average was estimated to infer a 
significant 2.9-fold increased risks for breast cancer, if causal, our data did not convincingly point 
to a trend of increasing risk with each increment in the probability of being an ATM mutation 
carrier. These derived risk estimates on the potential role of ATM heterozygosity were to a large 
extent driven by the highly increased risk for breast cancer seen in mothers of probands. Although 
the absence of a clear correlation with the likelihood of being a carrier may be due to the small 
number of breast cancer cases in each probability group, it does appear to detract from the 
hypothesis of a causal link between the ATM mutation and breast cancer and raises questions about 
the likelihood of a simple genetic relationship.  
The strengths of our study include the cohort design, the identification of study subjects from 
medical records, the unbiased identification of relatives through population registry linkage, the 
unbiased ascertainment and validation of cancer through cancer registry linkage, and the long 
(maximum, 60 years) and nearly complete follow-up of the entire study population. No family in 
the study was selected due to sporadic ATM gene mutation analyses of tumour tissue from cancer 
patients in the general population. The gene testing performed on tumour blocks from relatives 
affected with cancer was done after the identification of the patient and the relatives. Therefore, 
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only the gene probability score of the ancestors of the tested person changed, and not the score of 
the person him- or herself. This avoided a bias due to selection of study subjects for testing that by 
definition had a cancer. 
The observed excess risk for breast cancer among mothers is so large that neither chance nor 
confounding is a feasible explanation. Confounding would be possible if the mothers or other 
female relatives were less likely than the general population to have children or more likely to have 
children later in life (Ewertz et al, 1990). The reproductive pattern of the 66 families under study 
did not, however, indicate that either factor is of importance. On the contrary, we may have 
underestimated the strength of the association in female blood relatives in direct line with the AT 
patient (mothers, grandmothers and great-grandmothers), because the national rates of breast cancer 
are influenced by an approximately 30% higher risk for breast cancer among nulliparous women 
than among parous women. Confounding could also arise if the mothers of children with AT were 
more likely to undergo screening examinations for the early detection of breast cancer than the 
general population, because clinicians might be aware of the suggested link between ATM 
heterozygosity and breast cancer. This suggestion is, however, recent and is not yet widespread 
knowledge among colleagues or in affected families.  
Large studies of blood relatives of patients with AT from France (Janin et al, 1999), the United 
Kingdom (Inskip et al, 1999) and the USA (Swift et al, 1991; Athma et al, 1996) have consistently 
shown an increased incidence or mortality (UK study) of breast cancer among female family 
members. In a cross-sectional analysis of 33 cases of breast cancer diagnosed in female relatives of 
99 AT families in the USA, in which gene mutations were analysed, Athma and co-workers (1996) 
found a significantly increased odds ratio of 3.8 for breast cancer among ATM gene carriers 
compared with non-carriers. This is compatible with our estimate of a 2.7-fold increased risk for 
breast cancer among female mutation carriers in general. The analysis of the US family data 
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indicated, however, that the risk was increased among older women (≥ 60 years) in particular, 
which clearly contrasts with our observation of an increased risk for early-onset breast cancer. Our 
finding does, however, appear to concur with that of the French study, which based on 29 observed 
female breast cancer cases in blood relatives of 34 AT families found the excess risk for breast 
cancer to be higher among female relatives below the age of 45 than among female relatives above 
that age (Janin et al, 1999; Geoffroy-Perez  et al, 2001). Also, as in our study, the risk for breast 
cancer among female relatives in the French study seemed to be restricted to the subgroup of 
presumed obligate carriers (including the mothers of probands), with five observed cancers among 
young carriers, equivalent to a significantly increased relative risk of 4.6. These findings are 
compatible with the estimate of 7.1 among young (< 55 years) obligate carriers seen in our study. In 
the French study, the risks for breast cancer in the subgroups with estimated carrier probabilities of 
0,67, 0.50 and 0.25 were similar to that of the general population, also indicating the absence of a 
clear relationship between mutation carrier probability and breast cancer risk. Unfortunately, the 
risk for breast cancer among mothers was not given separately. In the study in the United Kingdom, 
only mothers (obligate carriers) and grandmothers (0.50 probability carriers) were included as 
female relatives of the 95 AT probands (Inskip et al, 1999). On the basis of three observed deaths 
from breast cancer in each group of female relatives, the risk of mothers was non-significantly 
increased (SMR, 3.4) and that of grandmothers was close to that of the general population (SMR, 
0.9), providing little support to a relationship between risk and carrier likelihood.    
Thus, to our minds, the combined data from the published studies of breast cancer risk in female 
relatives of AT patients demonstrate a substantial and consistent increase in the risk for mothers. 
The existing international data on the risks for breast cancer of other female relatives are, however, 
still not conclusive, and convincing data to support a simple relationship between likelihood of 
ATM heterozygosity and risk of breast cancer has not yet been presented. Our extended data from 
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the Nordic study showed no indication of variation in the risk for female breast cancer in analyses 
stratified according to the major characteristics of the probands or the families. An alternative 
hypothesis for the absence of a gradient of breast cancer incidence by increasing probability of 
being a gene carrier and the finding of an increased incidence mainly confined to mothers might be 
that giving birth to an AT child or having a pregnancy with a foetus affected with AT changes the 
mother’s breast cancer risk - in combination with or regardless of any effect of her ATM 
heterozygosity. One can speculate whether microchimerism during pregnancy, i.e. the phenomenon 
that foetal cells may pass into the maternal circulation and tissues, play a role in the highly 
increased risk of breast cancer seen among the mothers giving birth to an AT child. It has been 
suggested that microchimerism is associated with various immunological conditions of pregnancy 
and some chronic autoimmune conditions predominantly found in women (Bianchi, 2000), and in 
one study it has been associated with cervical cancer (Cha et al, 2003). It is conceivable that being 
pregnant with a foetus affected with AT may facilitate this biological phenomenon, and that the 
presence of foetal AT cells in the circulation or tissues of the mother may contribute to the 
development of maternal breast cancer. In our study, however, we saw no variation in breast cancer 
risk after stratification of mothers according to the number (one or two) of offspring affected by 
AT, although this conclusion is severely weakened by the small number of mothers and outcomes 
included. Detailed consistent data about pregnancies were not available in this study. 
We found a slight increased risk for cancers at all sites except breast, which reached statistical 
significance for female relatives only. There was a tendency for slight but non-significant elevations 
in risk for most diagnostic groups. Female relatives had excess numbers of cancers of the gall 
bladder and liver, which correlated with the mutation carrier probability of the subjects, but which 
was not replicated among male relatives. The slight increase seen for ovarian cancer was not 
correlated with mutation carrier probability or familial proximity to the proband; this was also the 
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case in the increased risk for malignant melanoma in male relatives. In one of their initial analyses 
of cancer incidence in blood relatives of AT patients Swift et al. (Swift et al, 1991) reported a 
significant 2.5-fold increase in the risk for cancers at all sites combined in male relatives (73 
observations) compared with that of spouses of female relatives (19 observations), and a significant 
3.9-fold increase in all cancers in male obligate heterozygotes (18 observations). A risk estimate for 
all cancers other than breast in female relatives was not made in this study, but our re-calculation on 
the basis of data reported in the paper indicates that the risk was much lower than that of male 
relatives. There is no good explanation for the observed difference between the two sexes in the US 
study, and there is no support in our study for a substantially increased risk for cancers among male 
relatives. In a separate analysis of the incidence of cancers at sites other than the breast, the French 
study obtained an overall RR of 0.9 for both sexes combined on the basis of 93 observations 
(Geoffroy-Perez et al, 2001). Liver was the only site for which there was a significant increase in 
risk, on the basis of six observed and 1.5 expected cases; sex-specific risks were, however, not 
given. Interestingly, there have been a few case-reports of hepatocellular carcinoma in AT patients, 
all in females (Weinstein et al, 1985; Kumar et al, 1979). 
The main limitation of our study, as well as other studies of cancer in AT families, is small study 
groups with associated low precision in risk estimation for site-specific cancers, including female 
breast cancer, ovarian cancer, lymphomas and leukaemias. This indicates the need for increased 
international collaboration in the study of cancer in AT families and, if feasible, a combined 
analysis of the available study materials. The hypothesis of breast cancer risk related to being 
pregnant with an AT-affected child also needs to be pursued. 
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Abstract
An Arg/Pro polymorphism in codon 72 of the TP53 gene
was analyzed in blood samples from 390 breast and 162
colorectal cancer patients previously investigated for
TP53 mutations in their tumors. Among the breast
cancer cases, 228 were homozygous for the Arg72
allele, of which, 65 (28.5%) also had a TP53 mutation
in their tumors. In contrast, of 26 cases that were
homozygous for the Pro72 allele, only 1 case (3.8%)
had a TP53 mutation in the tumor (P  0.004).
Cloning the TP53 gene from tumor DNA followed by
sequencing was performed in 14 heterozygotes with
tumor mutation, and 9 of the mutations resided on the
Arg72 allele. Among the colorectal cancer cases, no
difference in mutation frequency was seen between the
two different homozygotes, 40 TP53 mutations in 97
Arg72 homozygous cases (41.2%) versus 7 in 16 Pro72
homozygous cases (43.8%). These results suggest a
selective growth advantage for cells carrying a type of
TP53 mutation seen in breast carcinomas when the
mutation resides on an Arg72 allele.
Introduction
Mutations in the TP53 gene are considered to represent the
most common genetic alteration in human cancer. These mu-
tations (mostly missense mutations) may damage the normal
function of TP53 as a transcription factor, and the induction of
repair or apoptosis may be abolished. Consequently, other
genetic alterations may accumulate in the cell. In breast cancer,
the TP53 gene is mutated in 20–30% of the tumors and in
colorectal cancer in 50–60% [reviewed in Ref. 1].
In addition to gene mutations, several reports have focused
on TP53 polymorphisms as risk factors for malignant disease.
Two of 14 known polymorphisms located in the TP53 gene
alter the amino acid (International Agency for Research on
Cancer TP53 Mutation Database).5 The alleles of the polymor-
phism in codon 72, exon 4, encode an arginine amino acid
(CGC; Arg72) with a positive-charged basic side chain and a
proline residue (CCC; Pro72) with a nonpolar-aliphatic side
chain. Significant association between the codon 72 polymor-
phism and risk of cancer have been reported, although the
results with regard to most cancer diseases, including breast
(2–4) and colorectal carcinomas (5–7) remain inconclusive.
The Arg/Pro polymorphism is located in a proline-rich
region (residues 64–92) of the TP53 protein, where the Pro72
amino acid constitutes one of five PXXP motifs resembling a
SH3 binding domain. The region is required for the growth
suppression and apoptosis mediated by TP53 but not for cell
cycle arrest [reviewed in Ref. 1]. The two polymorphic variants
of wild-type TP53 have been shown to have some different
biochemical and biological properties (8) such as different
binding to components of the transcriptional machinery and
different activation of transcription, but they did not differ in
their ability to bind DNA.
The TP73 protein, a homologue of the TP53 protein, is
able to activate TP53-responsive promoters and induce apo-
ptosis in TP53-deficient cells. Marin et al. (9) recently showed
that some TP53 mutants can bind to and inactivate TP73 and
that the binding of such mutants was enhanced when the mu-
tation occurred on the Arg72 allele. They also reported a higher
frequency of TP53 mutations on the Arg72 compared with the
Pro72 allele in different squamous cell cancers. These findings
were supported by Tada et al. (10), which found an overrep-
resentation of mutations on the Arg72 allele in tumors from
different tissues. Interestingly, they found a preferential selec-
tion of the Arg72 allele in cancers with recessive TP53 mutants
(mutants that do not inactivate wild-type TP53 in a dominant
negative manner). It was suggested that recessive TP53 mutants
achieve a selective growth advantage by an Arg72-dependent
inactivation of TP73, whereas the dominant negative TP53
mutants inactivate the remaining wild-type TP53 allele in an
Arg72-independent manner.
We have investigated whether somatic TP53 mutations
exist in combination with a specific constitutional allele variant
of the codon 72 polymorphism (Arg72 or Pro72) in a series of
breast carcinomas and a series of colorectal carcinomas, which
are known to have different TP53 mutation spectrum.
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Materials and Methods
Materials. The study included 390 Norwegian breast cancer
cases. These were from two different consecutive series (129
and 130 samples, respectively) previously described (11, 12)
and from two series of advanced breast cancer cases (84 and 47,
respectively), of which, one has been described previously (13).
One hundred sixty-two Norwegian colorectal cancer cases pre-
viously analyzed for TP53 mutations in their tumors were also
included in this study (14). DNA had been isolated from both
blood cells and tumor tissue using chloroform/phenol extrac-
tion followed by ethanol precipitation (Nucleic Acid Extractor
340A; Applied Biosystems) according to standard procedure.
Genotyping. DNA from blood samples was analyzed for the
genetic variation in codon 72 in exon 4 of the TP53 gene using
Restriction Fragment Length Polymorphism analysis (15).
Genomic DNA (50 ng) was amplified in 25 l of PCR reactions
(Eppendorf Mastercycler Gradient), containing 12.5 pmol of
each primer (F: 5-TTGCCGTCCCAAGCAATGGATGA-3,
R: 5-TCTGGGAAGGGACAGAAGATGAC-3), 2.5 l of
10 buffer (Gene Amp from Applied Biosystems, containing
100 mM Tris-HCl, 500 mM KCl, 15 mM MgCl2, and 0.01% W/v
gelatin), 10 mM deoxynucleotide triphosphate, and 0.75 units of
AmpliTaq DNA Polymerase (Applied Biosystems). A 199-bp
fragment was amplified using a PCR program starting with
denaturation for 3 min at 94°C, followed by 35 cycles of 15 s
at 94°C, 15 s at 68°C, and 30 s at 72°C. Restriction analysis was
performed mixing 8 l of PCR product, 9 l of H2O, 2 l of
1 NEBuffer 2, 1 l of (10 units/l) BstUI (New England
BioLabs), and incubated for 3 h at 60°C. Electrophoresis in
7.5% acryl amide gel gave an allele pattern of the two alleles of
113 bp 86 bp (Arg) and 199 bp (Pro), respectively (Fig. 1A).
Mutation Analysis. TP53 mutation detection in tumor DNA
was performed using Constant Denaturing Gradient Gel Elec-
trophoresis (16) or Temporal Temperature Gradient Gel Elec-
trophoresis (17). The samples from the two advanced breast
cancer series (131 cases) have been screened for mutations in
exons 2–11 of the TP53 gene (13). One of the consecutive
breast cancer series (130 cases) has been reanalyzed to include
exons 2–11 (analysis of exons 5–8 reported in Ref. 12). The
samples from the other consecutive breast cancer series (129
cases; Ref. 11), as well as the colon cancer cases (162 cases;
Ref. 14) have been screened for TP53 mutations in exons 5–8.
Cloning and Sequencing. The cloning of the TP53 gene from
tumor DNA was performed using the TOPO TA Cloning kit
(Invitrogen). Four different fragments were designed to com-
prise the polymorphism in exon 4, as well as the respective
mutation (Fig. 1B). DNA (50 ng) was amplified in 25 l of
PCR reactions (Eppendorf Mastercycler Gradient), containing
12.5 pmol of each primer (for primer sequences see Table 1),
2.5 l of 10 buffer (Gene Amp; Applied Biosystems) giving
a concentration of 1.5 mM Mg2, 10 mM deoxynucleotide
triphosphate, and 0.75 units of AmpliTaq DNA Polymerase
(Applied Biosystems). The PCR program started with denatur-
ation for 2 min at 94°C, followed by 35 cycles of 15 s at 94°C,
15 s at 63°C, 60 s at 72°C, and finally 10 min at 72°C. The PCR
product was analyzed by gel electrophoresis (7.5% acrylamide)
Fig. 1. A, the TP53 codon 72 polymorphism
was analyzed in DNA from blood using RFLP.
Electrophoresis in 7.5% acrylamide gel gave an
allele pattern of the two alleles of 113 bp 86
bp (Arg) and 199 bp (Pro). The gel shows three
patients with different genotypes, along with
the sequence of a heterozygous sample. B, from
heterozygous samples (Arg72/Pro72) with a
TP53 mutation in their tumor, the TP53 gene
was cloned and sequenced to determine which
allele the mutation resided on. Four different
fragments were designed for cloning to include
the polymorphism in exon 4 as well as the
respective mutation (, mutations located in
exons 5–8). The part of the DNA sequence with
the polymorphism and mutation are shown
(mutations sequenced in reverse direction).
Table 1 Primers used for cloned inserts
Fragment Primer
Exon 4–5 (1319 bp) 4F: 5-gctggggggctgaggacc-3
5R: 5-gcaatcagtgaggaatcaga-3
Exon 4–6 (1527 bp) 6R: 5-ccactgacaaccaccctt-3
Exon 4–7 (2217 bp) 7R: 5-aggggtcagcggcaagcaga-3
Exon 4–8 (2679 bp) 8R: 5-aggcataactgcacccttgg-3
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Table 2 Overview of TP53 mutations found
Characterization and distribution of TP53 mutations in breast carcinomas with respect to genotype of the codon 72 polymorphism. The heterozygote samples that were
cloned and sequenced to determine which allele of the codon 72 the mutation resided on are shown in bold and the respective allele underlined. (The sample IDs are
designated MT and ULL for the two consecutive series, and LB and FU for the advanced breast cancer series.)
Sample ID
Genotype Mutation
Codon Codon change Base change Aminoacid Type
Codon 72 Exon
ULL-T-271 Arg/Arg 3 29 1bp ins ins A Frameshift
ULL-T-177 Arg/Arg 4 110 CGT  CCT G  C Arg  Pro Missense
LB 105 A Arg/Arg 5 1 bp upstream Intronic G  A Splice
ULL-T-096 Arg/Arg 5 18 bp ins In frame
ULL-T-038 Arg/Arg 5 138 GCC  GTC C  T Ala  Val Missense
LB 101 A Arg/Arg 5 151 CCC  TCC C  T Pro  Ser Missense
MT 064 Arg/Arg 5 156 CGC  CCC G  C Arg  Pro Missense
ULL-T-106 Arg/Arg 5 159 GCC  GAC C  A Ala  Asp Missense
LB 703 B Arg/Arg 5 168 CAC  CCC A  C His  Pro Missense
ULL-T-099 Arg/Arg 5 173 GTG  CTG G  C Val  Leu Missense
MT 193 Arg/Arg 5 174–180 17 bp del Frameshift
FU M312 Arg/Arg 5 175 CGC  CAC G  A Arg  His Missense
MT 083 Arg/Arg 5 175 CGC  CAC G  A Arg  His Missense
ULL-T-171 Arg/Arg 5 175 CGC  CAC G  A Arg  His Missense
LB 205 A Arg/Arg 5 176 TGC  TTC G  T Cys  Phe Missense
MT 101 Arg/Arg 5 181 CGC  CAC G  A Arg  His Missense
FU 07 Arg/Arg 6 3 bp upstream Intronic T  G Splice
LB 307 B Arg/Arg 6 190 CCT  CTT C  T Pro  Leu Missense
MT 120 Arg/Arg 6 194 CTT  CGT T  G Leu  Arg Missense
FU 23 Arg/Arg 6 195 ATC  ACC T  C Ile  Thr Missense
ULL-T-179 Arg/Arg 6 196 22 bp del Frameshift
FU M307 Arg/Arg 6 197–199 6 bp del In frame
LB 111 A Arg/Arg 6 204 GAG  TAG G  T Glu  Stop Nonsense
MT 078 Arg/Arg 6 204 GAG  TAG G  T Glu  Stop Nonsense
LB 805 A Arg/Arg 6 213 CGA  TGA C  T Arg  Stop Nonsense
ULL-T-188 Arg/Arg 6 216 GTG  ATG G  A Val  Met Missense
FU M326 Arg/Arg 6 217 GTG  ATG G  A Val  Met Missense
LB 123 A Arg/Arg 6 217–221 14 bp del Frameshift
MT 106 Arg/Arg 7 238 TGT  TTT G  T Cys  Phe Missense
LB 305 A Arg/Arg 7 239–242 11 bp del Frameshift
MT 050 Arg/Arg 7 242 TGC  TTC G  T Cys  Phe Missense
MT 359 Arg/Arg 7 242 TGC  TAC G  A Cys  Tyr Missense
MT 135 Arg/Arg 7 244–247 8 bp del Frameshift
MT 161 Arg/Arg 7 245 GGC  AGC G  A Gly  Ser Missense
LB 309 A Arg/Arg 7 248 CGG  CAG G  A Arg  Gln Missense
MT 024 Arg/Arg 7 248 CGG  CAG G  A Arg  Gln Missense
ULL-T-250 Arg/Arg 7 248 CGG  CAG G  A Arg  Gln Missense
MT 160 Arg/Arg 7 248 CGG  TGG C  T Arg  Trp Missense
LB 111 B Arg/Arg 7 249 AGG  GGG A  G Arg  Gly Missense
MT 071 Arg/Arg 7 251 ATC del C Frameshift
FU 27 Arg/Arg 7 256 12 bp ins In frame
FU M327 Arg/Arg 8 261–269 24 bp del In frame
LB 120 A Arg/Arg 8 266 GGA  AGA G  A Gly  Arg Missense
FU 26 Arg/Arg 8 273 CGT  CCT G  T Arg  Pro Missense
LB 107 B Arg/Arg 8 273 CGT  CAT G  A Arg  His Missense
LB 208 A Arg/Arg 8 273 CGT  CAT G  A Arg  His Missense
LB 405 A Arg/Arg 8 273 CGT  CAT G  A Arg  His Missense
FU M310 Arg/Arg 8 273 CGT  CAT G  LA Arg  His Missense
FU M321 Arg/Arg 8 273 CGT  TGT C  T Arg  Cys Missense
MT 029 Arg/Arg 8 273 CGT  CAT G  A Arg  His Missense
MT 240 Arg/Arg 8 273 CGT  CAT G  A Arg  His Missense
ULL-T-164 Arg/Arg 8 273 CGT  CAT G  A Arg  His Missense
ULL-T-071 Arg/Arg 8 273 CGT  GGT C  G Arg  Gly Missense
LB 706 A Arg/Arg 8 277 TGT  TAT G  A Cys  Tyr Missense
ULL-T-215 Arg/Arg 8 278 CCT  CTT C  T Pro  Leu Missense
MT 119 Arg/Arg 8 281 GAC  GGC A  G Asp  Gly Missense
FU 12 Arg/Arg 8 282 CGG  GGG C  G Arg  Gly Missense
MT 181 Arg/Arg 8 282 CGG  CAG G  A Arg  Gln Missense
ULL-T-154 Arg/Arg 8 282 CGG  TGG C  T Arg  Trp Missense
MT 003 Arg/Arg 8 285 GAG  AAG G  A Glu  Lys Missense
LB 404 B Arg/Arg 8 286 GAA  AAA G  A Glu  Cys Missense
LB 406 A Arg/Arg 9 2 bp upstream Intronic A  G Splice
FU M317 Arg/Arg 9 2 bp upstream Intronic A  G Splice
FU 04 Arg/Arg 9 1 bp downstream Intronic G  C Splice
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for quality check, then cloned into the pCR 2.1-TOPO vector
and transformed into Escherichia coli according to standard
protocols. The plasmid DNA was purified using QIAprep Spin
Miniprep Kit (Qiagen), and the complete insert was sequenced
(ABI 3100; Applied Biosystems) in overlapping fragments.
Statistics. Deviations from Hardy-Weinberg equilibrium of
the codon 72 polymorphism were determined using 2 test.
Cross-tabulation and 2 test were performed when studying the
polymorphism’s association with TP53 mutations. Pearson 2
test or Fisher’s exact test (when appropriate) was used, and
statistical significance level was set to P  0.05. Computations
were performed using Excel (Microsoft Excel 97) and SPSS
(version 8.0).
Results and Discussion
Among the 390 breast cancer cases genotyped, the allele fre-
quencies were 0.76 and 0.24 for the Arg72 and Pro72 allele,
respectively, and the polymorphism was shown to be in Hardy-
Weinberg equilibrium. The TP53 mutation frequencies in the
different series, where screening of exons 2–11 were per-
formed, were 14.6% (19 of 130) in the consecutive series and
28.6% (24 of 84) and 46.8% (22 of 47) in the two series of
advanced breast cancer cases, reflecting the different distribu-
tion of tumor size and stage of disease between these series. Of
the 228 cases that were homozygous for the Arg72, 65 (28.5%)
also carried a TP53 mutation in their tumors. In contrast, of the
26 cases that were homozygous for the Pro72 allele, only 1 case
(3.8%) had a TP53 mutation (Table 2). Thus, the occurrence of
a TP53 mutation was significantly more often found on the
Arg72 allele than the Pro72 allele (P  0.004). This skewed
distribution was seen in all series, although each of them was
too small to give significant results by their own. When limited
to TP53 mutations residing in exons 5–8, the same significant
biased distribution was seen (P  0.007). Only 8 of 65 muta-
tions (12.3%) were located outside exons 5–8, of which, 6 were
found in Arg72 homozygous and 2 in heterozygous (Table 2).
The same skewed distribution with respect to genotype was also
seen when considering only missense mutations. Of the 228
homozygotes for the Arg72 allele, 45 (19.7%) missense muta-
tions were found, whereas none of the 26 homozygotes for the
Pro72 allele carried a missense mutation (P  0.006).
From 14 heterozygotes (Arg72/Pro72) with a TP53 muta-
tion in their tumor and where enough tumor DNA still was
available, the TP53 gene was cloned and sequenced to deter-
mine which allele the mutation resided on (Fig. 1B). In 9 cases,
the mutations (5 missense, 2 nonsense, and 2 frameshifts) were
located on the arginine allele, and in the 5 remaining samples,
the mutations (2 missense, 1 frameshift, and 1 deletion) resided
on the Pro allele supporting the findings in the homozygous
samples (Table 2).
The observed skewed occurrence of somatic TP53 muta-
tions on the Arg72 allele in breast carcinomas suggests that this
combination gives breast epithelial cells a growth advantage,
which may increase the risk of malignant transformation and
development of cancer. The coexistence of the Arg72 with a
mutation may modify the TP53 protein structure in a way that
Table 2 Continued
Sample ID
Genotype Mutation
Codon Codon change Base change Aminoacid Type
Codon 72 Exon
FU M314 Arg/Arg 10 342 CGA  TGA CST Arg Stop Nonsense
ULL-T-263 Arg /Pro 4 89 11 bp ins Frameshift
ULL-T-113 Arg /Pro 4 113 TTC  GTC T  G Phe  Val Missense
MT 059 Arg /Pro 5 134 TTT  CTT T  C Phe  Leu Missense
LB 709 B Arg /Pro 5 136 CAA  TAA C  T Gln Stop Nonsense
FU 11 Arg /Pro 5 140–143 10 bp del Stop169 Frameshift
FU M315 Arg /Pro 5 142 CCT del C Stop169 Frameshift
MT 052 Arg /Pro 5 156 CGC  CCC G  C Arg  Pro Missense
LB 115 B Arg /Pro 5 163 TAC  TGC A  G Tyr  Cys Missense
LB 708 B Arg /Pro 5 165 CAG  TAG C  T Gln Stop Nonsense
FU M304 Arg /Pro 5 167 CAG  TAG C  T Gln Stop Nonsense
MT 022 Arg /Pro 5 172 GTT del T Frameshift
MT 020 Arg /Pro 5 174–180 17 bp del Frameshift
ULL-T-155 Arg /Pro 5 175 CGC  CAC G  A Arg  His Missense
MT 208 Arg /Pro 5 179 CAT  TAT C  T His  Tyr Missense
FU 05 Arg /Pro 6 195 ATC  ACC T  C Ile  Thr Missense
MT 111 Arg /Pro 6 195 ATC  ACC T  C Ile  Thr Missense
ULL-T-007 Arg /Pro 6 195 ATC  ACC T  C Ile  Thr Missense
FU M316 Arg /Pro 6 220 TAT  TGT A  G Tyr  Cys Missense
ULL-T-226 Arg /Pro 6 220 TAT  TGT A  G Tyr  Cys Missense
LB 303 B Arg /Pro 7 232–234 6 bp del In frame
LB 206 A Arg /Pro 7 237 ATG  ATT G  T Met  Ile Missense
MT 104 Arg /Pro 7 239 AAC  ACC A  C Asn  Thr Missense
FU M303 Arg /Pro 7 248 CGG  TGG C  T Arg  Trp Missense
MT 112 Arg /Pro 7 248 CGG  TGG C  T Arg  Trp Missense
MT 132 Arg /Pro 7 248 CGG  CAG G  A Arg  Gln Missense
MT 016 Arg /Pro 8 273 CGT  CAT G  A Arg  His Missense
MT 065 Arg /Pro 8 273 CGT  CAT G  A Arg  His Missense
FU M301 Arg /Pro 8 282 CGG  GGG C  G Arg  Gly Missense
MT 318 Arg /Pro 8 282 CGG  TGG C  T Arg  Trp Missense
FU 06 Arg /Pro 8 298 GAG  TAG G  T Glu Stop Nonsense
LB 122 A Pro /Pro 5 1 bp upstream Intronic G  A Splice
1687Cancer Epidemiology, Biomarkers & Prevention
interferes either with the protein’s ability to achieve sequence-
specific binding to DNA or with the interaction and recruitment
of the transcription machinery, causing an altered transcription
pattern (18). Another possibility is that the Arg72 may modify
the mutant TP53 protein’s ability to bind to and interact with
other proteins such as, for example, TP73. Interaction between
tumor-derived TP53 mutants and TP73 has been observed (19),
and the codon 72 polymorphism has been reported to be a
modifier of such an interaction (9), which may interfere with
TP73-induced apoptosis.
The same level of skewed distribution of mutations resid-
ing on the Arg72 as seen for all type of mutations was also seen
for missense mutations, giving no evidence for a stronger effect
of such mutations. However, missense mutations are of many
different types, and classifications according to structure or
function in different cell types in larger series may give other
results. The more severe changes like deletion, insertion, non-
sense, and splice mutations may lead to a truncated protein or
lack of protein where a codon 72 polymorphism has no mod-
ifying impact. Analyzing nonmissense mutations as one group
with respect to the codon 72 homozygotes gave no skewed
distribution (P  0.710). The number is, however, small, and
even truncated TP53 proteins may have an impact through
mechanisms like inactivating other proteins (e.g., TP73) if their
interacting domain is intact and the protein is stable. It cannot
be excluded that the two polymorphic variants may have dif-
ferent effects also on such mutants.
Genotyping of the 162 colorectal cancer cases revealed
allele frequencies of the Arg72 and Pro72 alleles of 0.75 and
0.25, respectively. The TP53 mutation frequency in this cohort
was 48.1%. In contrast to the breast cancer cases, no difference
in the frequency of mutations between the two different ho-
mozygotes was found in the colorectal cancer cases, with 40
TP53 mutations in 97 Arg72 homozygous cases (41.2%) versus
7 TP53 mutations in 16 Pro72 homozygous cases (43.8%). The
spectrum of mutations is different between these two tumor
types,6 partly attributable to tissue-specific differences in car-
cinogen exposure and in metabolism (reviewed in Ref. 1).
Breast cancer is reported to have a high level of insertions,
deletions, and nonsense mutations, and GC:AT transitions are
the most frequent change, equally distributed between CpG and
non-CpG areas, whereas colorectal cancer has a high frequency
of CpG transitions leading to mutants with a presumable dom-
inant negative effect (1). A recent report divided the mutations
into two groups according to their predicted dominant negative
or recessive characteristics based on the results of a transacti-
vation assay (9), and the authors proposed that it was only the
recessive mutations that preferentially was located on the
Arg72 allele (10). The dominant negative mutants were sug-
gested to be independent of the codon 72 polymorphism. Using
the same criteria for classifying the mutations as proposed by
Tada et al. (10) on our series, the frequency of dominant
negative mutants were higher in the colorectal cancer cases
(83.3%, 30 of 36) than in the breast cancer cases (61.1%, 22 of
36; P  0.064). Although only a minor fraction of our mutants
(72 of 175) could be classified according to these categories,
these results nevertheless support the hypothesis that a tumor-
igenic effect of the Arg72 allele only occurs when combined
with a somatic mutation of the type seen in breast carcinomas.
Additional studies, including functional assays, are warranted
to explore the effects of the different combined variants and
their role in tumorigenesis in different tissues.
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